Advertisement

β-Receptorenblocker

Conference paper
Part of the Ergebnisse der Inneren Medizin und Kinderheilkunde book series (KINDERHEILK. NF, volume 30)

Zusammenfassung

Der pharmakologische Receptorbegriff hat eine lange Vorgeschichte. Paul Ehrlich entwickelte die Vorstellung, daß jede pharmakologisch wirksame Substanz wenigstens zwei getrennte funktionelle Strukturanteile besitzt, eine haptophore Gruppe, bestimmend für die Verteilung des Pharmakons im Körper und die selektive Bindung an die jeweiligen Erfolgsorgane, und eine pharmakophore Gruppe, der die spezifischen Wirkungen des Pharmakons auf die Erfolgsorgane zuzuordnen sind. Die Annahme eines haptophoren Strukturanteils am Pharmakon setzt entsprechende spezifische Empfänger bzw. Receptoren am jeweiligen Erfolgsorgan voraus. Von Langley wurde 1905 der Receptorbegriff zur Deutung der Curarewirkung an der quergestreiften Skelet-Muskulatur entwickelt. Auch für ihn waren die „receptiven Substanzen“bestimmte Komponenten der Zellen, mit denen sich pharmakologisch wirksame Substanzen verbinden müssen, um ihre spezifischen Wirkungen auslösen zu können.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Åberg, G., Dzedin, T., Lundholm, L., Olsson, L., Svedmyb, N.: A comparative study of some cardiovascular effects of Sotalol (MJ 1999) and propranolol. Life Sei. 8, 353–365 (1969).Google Scholar
  2. Åblad, B., Brogard, M., Ek, L.: Pharmacological properties of H 56/28- a β-adrenergic receptor antagonist. Acta pharmacol. (Kbh.) 25, Suppl. II, 9–40 (1967 b).Google Scholar
  3. Åblad, B., Johnsson, G., Norby, A., Sölvell, L.: Potency and time — effect relationship in man of propranolol and H 56-28 — comparative studies after oral administration. Acta Pharmacol. (Kbh.) 25, 85–94 (1967 a).Google Scholar
  4. Abramson, E. A., Arky, R. A., Woeber, K. A.: Effect of propranolol on the hormonal and metabolic response to insulin–induced hypoglycaemia. Lancet 1966 II, 1386–1388.Google Scholar
  5. Achari, G., Sinha, S. P.: Anti-tremor action of propranolol (Inderal). Jap. J. Pharmacol. 17, 679–680 (1967).PubMedGoogle Scholar
  6. Ackenheil, M., Kusus, T., Niklas, M., Daniel, W., Schierl, W., Lydtin, H.: Über den Einfluß von Propanolol auf die renale Catecholaminausscheidung bei der Hypertonie (i. Druck).Google Scholar
  7. Ahlquist, R. P.: A study of the adrenotropic receptors. Amer. J. Physiol. 153, 586–600 (1948).PubMedGoogle Scholar
  8. Ahlquist, R. P.: The adrenergic receptor. J. pharm. Sei. 55, 359–367 (1966).Google Scholar
  9. Alleyne, G. 0., Dickinson, C. J., Dornhorst, A. C., Fulton, R. M., Green, K. G., Hill, I. D., Hurst, P., Laurence, D. R., Pilkington, T., Prichard, B. N. C., Robinson, B., Rosenheim, M. L.: Effect of pronethalol in angina pectoris. Brit. med. J. 1963 II, 1226.Google Scholar
  10. Alvaro, A. B., Macalpin, R. N., Kattus, A. A., Jr.: Effect of propranolol and nitroglycerin on exercise tolerance in angina pectoris (P). Circulation 36, Suppl. II, 51 (1967).Google Scholar
  11. Ammon, H. P. T., Estler, C.-J.: Tierexperimentelle Untersuchungen zur Pathogenese der Fettleber nach chronischer Alkohol Verabreichung. Klin. Wschr. 44, 650–652 (1966).PubMedGoogle Scholar
  12. Amsterdam, E. A., Wolfson, S., Gorlin, R.: Effect of therapy on survival in angina pectoris. Ann. intern. Med. 68, 1151 (1968).Google Scholar
  13. Anlauf, M., Heimsoth, V., Ulrych, M., Bock, K. D.: Vergleichende Untersuchung von zwei ß-Receptorenblockern auf den erhöhten Blutdruck und die Nierenfunktion. Verh. dtsch. Ges. inn. Med. 75, 16 (1969).Google Scholar
  14. Anthony, J. R., Jick, H., Spodick, D. H.: Control of persistent ventricular ectopic beats by alprenolol, a new beta — adrenergic blocking agent. Amer. Heart J. 77, 598–602 (1969).PubMedGoogle Scholar
  15. Antonis, A., Clark, M. L., Hodge, R. L., Molony, M., Pilkington, T. R. E.: Receptor mechanism in the hyperglycaemic response to adrenaline in man. Lancet 1967 I, 1135–1137.Google Scholar
  16. Areskog, N. H., Adolfsson, L., Rasmuson, T.: Effects of alprenolol and sorbidnitrate at exercise in patients with coronary insufficiency. Scand. J. clin. Lab. Invest. Suppl. 110, 114 (1969).Google Scholar
  17. Ariens, E. J.: The structure, activity relationships of beta-adrenergic drugs and beta adrenergic blocking drugs. Ann. N. Y. Acad. Sei. 139, 606–631 (1967a).Google Scholar
  18. Ariens, E. J.: Wirkung und Wirkungsmechanismus von Katecholaminen und ihren Derivaten. Naunyn- Schmiedebergs Arch.-Pharmak. exp. Path. 257, 118–141 (1967b).Google Scholar
  19. Arvidsson, J., Jurna, I., Steg, G.: Striatal and spinal lesions eliminating reserpine and physostigmine rigidity. Life Sei. 6, 2017–2020 (1967).Google Scholar
  20. Åström, H.: Haemodynamic effects of beta-adrenergic blockade. Brit. Heart. J. 30, 44–49 (1968).PubMedGoogle Scholar
  21. Balcon, R., Jewitt, D. E., Davies, J. P. H., Oram, S.: A controlled trial of propranolol in acute myocardial infarction. Lancet 1966 I, 918.Google Scholar
  22. Balcon, R., Jewitt, D. E., Davies, J. P. H., Oram, S.: A controlled trial of propranolol in acute myocardial infarction. Amer. Heart J. 74, 582–584 (1967).PubMedGoogle Scholar
  23. Barden, T. P., Stander, R. W.: Myometrial and cardiovascular effects of an adrenergic blocking drug in human pregnancy. Amer. J. Obstet. Gynec. 101, 91–99 (1968a).PubMedGoogle Scholar
  24. Barden, T. P., Stander, R. W.: Effects of adrenergic blocking agents and catecholamines in human pregnancy. Amer. J. Obstet. Gynec. 102, 226–235 (1968b).PubMedGoogle Scholar
  25. Barrett, A. M., Crowther, F., Dunlop, D., Shanks, R. J., Smith, L. M.: Cardio-selective beta-blockade. Naunyn-Schmiedebergs Arch.-Pharmak. exp. Path. 259, 152–153 (1968).Google Scholar
  26. Barrett, A. M., Culltjm, V. A.: The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Brit. J. Pharmacol. 34, 43–55 (1968).Google Scholar
  27. Barrett, A. M., Fitzgerald, J. D.: What is a ß-Blocker. Amer. Heart J. 76, 712–714 (1968).Google Scholar
  28. Bassenge, E., Walter, P., Doutheil, U.: Wirkungsumkehr der adrenergischen Coronargefäßreaktion in Abhängigkeit vom Coronargefäßtonus. Pflügers Arch. ges. Physiol. 297, 146–155 (1967).Google Scholar
  29. Bath, J. C.: Treatment of cardiac arrhythmias in unanesthetized patients. Role of adrenergic beta receptor blockade. Amer. J. Cardiol. 18, 415–425 (1966).PubMedGoogle Scholar
  30. Battock, D. J., Alvarez, H., Chidsey, Ch. A.: Effects of propranolol andisorbidedinitrate on exercise performance and adrenergic activity in patients with angina pectoris. Circulation 39, 157–169 (1969).PubMedGoogle Scholar
  31. Bay, G., Lund-Larsen, P., Lorentsen, E., Sivertssen, E.: Haemodynamic effects of pro-pranolol (Inderal) in acute myocardial infarction. Brit. med. J. 1907 I, 141–143.Google Scholar
  32. Belleau, B.: Stereo-chemistry of adrenergic receptors: newer concepts on the molecular mechanism of action of catecholamines and anti-adrenergic drugs at the receptor level. Ann. N. Y. Acad. Sei. 139, 580–605 (1967).Google Scholar
  33. Beluveau, R. E., Co vino, B. G.: Effects of a new β-adrenergic receptor blocking agent, alprenolol, and its optical isomers. Arch. int. Pharmacodyn. 180, 341–349 (1969).Google Scholar
  34. Bello, C. T., Sevy, R. W., Harakal, C., Hillyer, P. N.: Relationship between clinical severity of disease and hemodynamic patterns in essential hypertension. Amer. J. med. Sei. 253, 194–199 (1967).Google Scholar
  35. Benda, L., Doneff, D., Lujf, A., Moser, K.: Experimentelle und klinische Untersuchungen mit Iproveratril. Wien. med. Wschr. 117, 829–838 (1967).Google Scholar
  36. Bender, F., Kojima, N., Reploh, H. D., Oelmann, J.: Behandlung taehykarder Rhythmusstörungen des Herzens durch ß-Receptorenblockade des Atrioventrikulargewebes. Med. Welt (Stuttg.) (N. F.), 17, 1120–1123 (1966).Google Scholar
  37. Bender, F.: Behandlung von Herzrhythmusstörungen mit ß-Receptorenblockern. Wien. med. Wschr. 118, 820–821 (1968a).PubMedGoogle Scholar
  38. Bender, F.: Zum Problem der Dosierung bei der Behandlung von Sinustachykardien mit β-Reeeptoren-blockern. Med. Welt (Stuttg.) 19, 2481–2483 (1968 b).Google Scholar
  39. Benfey, B. G., Varma, D. R.: Antisympathomimetic and antifibrillatory effects of pronethalol and propranolol. Brit. J. Pharmacol. 26, 3–8 (1966).PubMedGoogle Scholar
  40. Benfey, B. G., Varma, D. R.: Interactions of sympathomimetic drugs, propranolol and phentolamine, on atrial refractory period and contractility. Brit. J. Pharmacol. 30, 603–611 (1967).PubMedGoogle Scholar
  41. Bennett, A., Whitney, B.: A pharmacological investigation of human isolated stomach. Brit. J. Pharmacol. 27, 286–298 (1966).PubMedGoogle Scholar
  42. Bergmann, R. K., Munoz, J.: Protection against histamine shock by catecholamines in bordetella pertussis-treated, adrenalectomized or adrenergic blocked mice. Proc. Soc. exp. Biol. (N. Y.) 122, 428 - 433 (1966).Google Scholar
  43. Berk, J. L., Hägen, J. F., Beyer, W. H., Dochat, G. R., La Pointe, R.: The treatment of hemorrhagic shock by beta adrenergic receptor blockade. Surg. Gynec. Obstet. 125, 311–318 (1967).Google Scholar
  44. Berk, J. L., Hägen, J. F., Dunn, J. M.: Treatment of septic shock with beta adrenergic blockade. Circulation 40, Suppl. Ill, 44 (1969).Google Scholar
  45. Bernheimer, H., Birkmayer, W., Hornykiewicz, O.: Zur Biochemie des Parkinson-Syn- droms des Menschen. Klin. Wschr. 41, 465–469 (1963).Google Scholar
  46. Bernheimer, H., Hornykiewicz, 0.: Dopaminumsatz im Gehirn von normalen und parkinsonkranken Menschen. Wien. Z. Nervenheilk. 23, 110–116 (1966).Google Scholar
  47. Besterman, E. M. M., Friedlander, D. H.: Clinical experiences with propranolol. Postgrad, med. J. 41, 526–535 (1965).Google Scholar
  48. Bett, J. H.: Hypotension after oral propranolol. Lancet 1968 I, 302.Google Scholar
  49. Beumer, H. M.: Inhalation of beta-adrenergic blockers by asthmatics. Lancet 1967 II, 993.Google Scholar
  50. Beumer, H. M.: Local effects of beta-adrenergic blocking drugs in histamin sensitive asthmatics. Pharmacol. Clin. 1, 172–173 (1969).Google Scholar
  51. Bewsher, P. D.: Propranolol, blood-sugar, and exercise. Lancet 1967 I, 104.Google Scholar
  52. Bewsher, P. D., Hillman, C. C., Ashmore, J.: Studies on the inhibition of insulin action in vitro by beta- adrenergic blocking agents. Ann. N. Y. Acad. Sei. 139, 891–896 (1967).Google Scholar
  53. Birkett, D. A., Chamberlain, D. A.: Beta-adrenergic blockade in angina pectoris: A method of treadmill assessment. Brit. med. J. 1966 II, 500–502.Google Scholar
  54. Bishop, J. M., Segel, N.: The circulatory effect of intravenous pronethalol in man at rest and during exercise in the supine and upright positions. J. Physiol. (Lond.) 169, 112 (1963).Google Scholar
  55. Björntorp, P., Ek, L., Olsson, S., Schröder, G.: The effect of a β-adrenergic receptor antagonist (H 56/28) on lipid mobilization. Acta pharmacol. (Kbh.) 25, Suppl. II, 51–62 (1967).Google Scholar
  56. Black, J. W., Crowther, A. F., Shanks, R. G., Smith, L. H., Dornhorst, A. C.: A new adrenergic beta-receptor antagonist. Lancet 1964 I, 1080–1081.Google Scholar
  57. Black, J. W., Duncan, W. A. M., Shanks, R. G.: Comparison of some properties of pronethalol and propranolol. Brit. J. Pharmacol. 25, 577–591 (1965).PubMedGoogle Scholar
  58. Black, J. W., Stephenson, J. S.: Pharmacology of a new adrenergic β-receptor blocking compound (nethalide). Lancet 1962II, 311–314.Google Scholar
  59. Blinks, J. R.: Evaluation of the cardiac effects of several beta-adrenergic blocking agents. Ann. N. Y. Acad. Sei. 139, 673–685 (1967).Google Scholar
  60. Bliss, H. A., Moffat, J. E., Gantt, C. L.: Effects of chronic oral propranolol therapy in idiopathic hypertrophic subaortic stenosis. Circulation 36, Suppl. II, 72 (1967).Google Scholar
  61. Bloomfield, D. A., Sowton, E.: Rate-independent effects of propranolol. The differentiation between chronotropic, inotropic and peripheral vascular responses. Circulât. Res. 21, Suppl. III, 243–247 (1967).Google Scholar
  62. Bohr, D. F.: Adrenergic receptors in coronary arteries. Ann. N. Y. Acad. Sei. 139, 799–807 (1967).Google Scholar
  63. Bollinger, A., Gander, M., Forster, G.: Pulsfrequenz und Leistungsfähigkeit vor und nach ß-Receptoren-Blockade durch Propranolol. Schweiz, med. Wschr. 95, 1075–1079 (1965).Google Scholar
  64. Bollinger, A., Simon, H. J.: Einfluß adrenergischer β-Receptoren-Blockade auf die Unterarmdurchblutung bei Patienten mit hyperkinetischem Herzsyndrom und vegetativer Ruhetachykardie. Dtsch. med. Wschr. 92, 28–30 (1967).PubMedGoogle Scholar
  65. Bond, P. A.: Metabolism of propranolol (Inderal), a potent, specific beta-adrenergic receptor blocking agent. Nature (Lond.) 213, 721 (1967).Google Scholar
  66. Bond, P. A., Howe, R.: The metabolism of pronethalol. Biochem. Pharmacol. 16, 1261–1280 (1967).PubMedGoogle Scholar
  67. Boreus, L. O., Broberger, U., NergArd, A., Zetterqvist, P.: Malignant pheochromocytoma in a child: treatment with a combination of alpha- and beta-adrenergic blockade. Acta paediat. scand. 57, 36–40 (1968).PubMedGoogle Scholar
  68. Botti, G., Visioli, O., Ambanelli, U.: Sur l’activité antiarythmique d’un nouvel agent de blocage beta-adrenergique. Cardiologia (Basel) 49, 45–58 (1966).Google Scholar
  69. Bowman, W. C., Râper, C.: Adrenotropic receptors in skeletal muscle. Ann. N. Y. Acad. Sei. 139, 741–753 (1967).Google Scholar
  70. Brachfeld, N., Gorlin, R.: Idiopathic hyperkinetic state: New clinical syndrome. Brit. Heart J. 22, 353–360 (1960).PubMedGoogle Scholar
  71. Braunsteiner, H., Dienstl, F.: Hemmung des Eosinophilensturzes nach Adrenalin durch Blockade adrenerger β-Receptoren. Klin. Wschr. 45, 48–49 (1967).PubMedGoogle Scholar
  72. Braunwald, E., Brockenbrough, E. C., Frye, R. L.: Studies on digitalis V. Comparison of the effects of ouabain on left ventricular dynamics in valvular aortic stenosis and hypertrophic subaortic stenosis. Circulation 26, 166–173 (1962).PubMedGoogle Scholar
  73. Braunwald, E., Cohen, L. S.: Amelioration of exercise induced angina pectoris in idiopathic hypertrophic subaortic stenosis with β-adrenergic blockade. Circulation 34, Suppl. Ill, 64–65 (1966).Google Scholar
  74. Braunwald, E., Ebert, P. A.: Hemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. Amer. J. Cardiol. 10, 489–495 (1962).PubMedGoogle Scholar
  75. Braunwald, E., Lambrew, C. T., Harrison, C. C., Morrow, A. G.: The haemodynamic effects of circulatory drugs in patients with idiopathic hypertrophic subaortic stenosis. Ciba Symp. 1964, 172 –188.Google Scholar
  76. Breining, H., Strubelt, O.: Die Bedeutung der adrenergischen ß-Receptoren für die cardio-toxische Wirkung sympathicomimetischer Amine. Med. Pharmacol, exp. 13, 169–176 (1965).Google Scholar
  77. Brewster, W. R. J., Isaacs, J. P., Osgood, P. F., King, T. L.: The hemodynamic and metabolic interrelationsship in the activity of epinephrine, norepinephrine and thyroid hormones. Circulation 13, 1–20 (1956).PubMedGoogle Scholar
  78. Brick, I., Glover, W. E., Hutchison, K. J., Roddie, I. C.: Effects of propranolol on peripheral vessels in man. Amer. J. Cardiol. 18, 329–332 (1966 c).Google Scholar
  79. Brick, I., Hutchison, K. J., Roddie, J. C.: The effect of beta adrenergic receptor blockade on the vasodilator response in the forearm to voluntary hyperventilation. J. Physiol. (Lond.) 187, 645–649 (1966a).Google Scholar
  80. Brick, I., Hutchison, K. J., Roddie, J. C.: The effect of propranolol in the responses of the rat isolated heart to noradrenaline. Brit. J. Pharmacol. 28, 324–327 (1966b).PubMedGoogle Scholar
  81. Brick, I., Hutchison, K. J., McDevitt, D. G., Roddie, I. C., Shanks, R. G.: Comparison of the effects of I. C. I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Brit. J. Pharmacol. 34, 127–140 (1968).Google Scholar
  82. Brink, A. J., Lewis, C. M.: Coronary blood flow and myocardial metabolism in obstructive cardiomyopathy. Observations before and after treatment with a beta adrenergic blocking agent. Amer. J. Cardiol. 19, 548–555 (1967).PubMedGoogle Scholar
  83. Brooker, W. D., Calvert, D. N.: Blockade of catecholamine mediated release of free fatty acids from adipose tissue in vitro. Arch. int. Pharmacodyn. 169, 117–130 (1967).Google Scholar
  84. Brooks, H., Banas, J., Jr., Meister, St., Szucs, M., Jr., Dalen, J., Dexter, L.: Sotalol- induced beta blockade in cardiac patients. Circulation 40, Suppl. III, 51 (1969).Google Scholar
  85. Brown, J. H., Rigillo, D. A.: Effects of Sotalol (MJ 1999) and propranolol on insulin — induced hypoglycemia in the rat. Proc. Soc. exp. Biol. (N. Y.) 127, 1158–1160 (1968).Google Scholar
  86. Brunner, H., Meier, M., Hedwall, P. R., Mattre, L.: Untersuchungen zur Klärung des Antagonismus von Propranolol gegen die Wirkung von Antihypertensiva. Arch. exp. Path. Pharmacol. 251, 132–133 (1965).Google Scholar
  87. Büchner, CH., Schilli, W., Gebhardt, W.: Die Wirkung adrenalinhaltiger Lokalanaesthe- tika nach Vorbehandlung mit Propranolol (Dociton). Kreisl. Bücherei 23, 97–101 (1967).Google Scholar
  88. Buckle, R. M.: Treatment of thyroid crisis by beta-adrenergic blockade. Acta endocr. (Kbh.) 57, 168–176 (1968).Google Scholar
  89. Burns, J. J., Salvador, R., Lemberger, L.: Metabolic blockade by methoxamine and its analogs. Ann. N. Y. Acad. Sei. 139, 833–840 (1967).Google Scholar
  90. Butcher, R. W.: K CYCLIC 3, 5-AMP and the lipolytic effects of hormones on adipose tissue. Pharmacol. Rev. 18, 237–241 (1966).PubMedGoogle Scholar
  91. Butcher, R. W., Sutherland, E. W.: The effect of catecholamines, adrenergic blocking agents, prostaglandin E 1, and insulin on cyclic AMP levels in the rat epididymal fat pad in vitro. Ann. N. Y. Acad. Sei. 139, 849–859 (1967).Google Scholar
  92. Cannon, W. B., Rosenblueth, A.: Automatic neuroeffector systems. New York: MacMillan Co., 1937.Google Scholar
  93. Carmeliet, E. E., Yerdonck, F.: Interaction of ouabain and a new beta-adrenergic receptor antagonist on K flux in cardiac muscle. Arch. int. Pharmacodyn. 162, 242–243 (1966).Google Scholar
  94. Carmeliet, E. E., Yerdonck, F.: Interaction between ouabain and butridine, a beta-adrenergic blocking substance, on the heart. Europ. J. Pharmacol. 1, 269–277 (1967).Google Scholar
  95. Cerasi, E., Effendic, S., Luft, R.: Role of adrenergic receptors in glucose-induced insulin secretion in man. Lancet 1969II, 301–302.Google Scholar
  96. Chamberlain, D. A.: Effects of beta-adrenergic blockade on heart size. Amer. J. Cardiol. 18, 321–328 (1966).PubMedGoogle Scholar
  97. Chamberlain, D. A., Howard, J.: The haemodynamic effects of β-sympathetic blockade. Brit. Heart J. 26, 213 (1964).PubMedGoogle Scholar
  98. Chamberlain, D. A., Turner, P., Sneddon, J. M.: Effects of atropine on heart-rate in healthy man. Lancet 1967 II, 12–15Google Scholar
  99. Cherchi, A., Lixi, M., Mazza, B., Camoglio, E.: Preliminary clinical report on the anti-arrhythmic effect of propranolol a new ß-receptor blocker. Minerva med. 57, 317–327 (1966 c).Google Scholar
  100. Cherian, G., Brockington, I. F., Shah, P. M., Oakley, C. M., Goodwin, J. F.: Beta-adrenergic blockade in hypertrophic obstructive cardiomyopathy. Brit. med. J. 19661a, 895–898.Google Scholar
  101. Cherian, G., Brockington, I. F., Shah, P. M., Oakley, C. M., Goodwin, J. F.: Beta adrenergic blockade in hypertrophic obstructive cardiomyopathy. Amer. J. Cardiol. 18, 481–484 (1966b).Google Scholar
  102. Chidsey, C. A., Jamieson, G., Vogel, J. H. K.: Cardiac adrenergic activity in experimental heart failure assessed with beta-receptor blockade. Circulation 36, Suppl. II, 85 (1967).Google Scholar
  103. Clausen, J., Schönau, F., Jörgensen, Rain, J., Felsby, M., Lyager Nielsen, B., Strange, B.: Absence of prophylactic effect of propranolol in myocardial infarction. Lancet 1900II, 920–924.Google Scholar
  104. Cogel, J., Overy, H., Brammell, H., Page, H., Paton, B.: Effects of isomers of propranolol on the pressure loaded ventricle. Clin. Res. 14, 129 (1966).Google Scholar
  105. Cohen, G. F.: Propranolol and J131 for thyrotoxicosis. Lancet 1908 II, 1349–1350.Google Scholar
  106. Cohen, L. S., Braunwald, E.: Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation 35, 847–851 (1967a).PubMedGoogle Scholar
  107. Cohen, L. S., Buccino, R. A., Morrow, A. G., Braunwald, E.: Recurrent ventricular tachycardia and fibrillation treated with a combination of beta-adrenergic blockade and electrical pacing. Ann. intern. Med. 60, 945–949 (1967b).Google Scholar
  108. Cole, A. F., Jacobs, J. A.: Propranolol in the management of cardiac arrhythmias during hypothermia. Canad. Anesth. Soc. J. 14, 44–48 (1967).Google Scholar
  109. Conway, N., Seymour, J., Gelson, A.: Cardiac failure in patients with valvar heart disease after use of propranolol to control atrial fibrillation. Brit. med. J. 1908 II, 213–214.Google Scholar
  110. Cote, G.: The effect of propranolol on human intraocular pressure. Canad. J. Ophthal. 3, 207–212 (1968).PubMedGoogle Scholar
  111. Crago, R. M., Eckholdt, J. W., Wisell, J. G.: Pheochromocytoma. Treatment with alpha- and beta-adrenergic blocking drugs. J. Amer. med. Ass. 202, 870–874 (1967).Google Scholar
  112. Craythorne, N. W. B., Huffington, P. E.: Effects of propranolol on the cardiovascular response to cyclopropane and halothane. Anesthesiology 27, 580–583 (1966).PubMedGoogle Scholar
  113. Crema, A., Benzi, G., Frigo, G. M., Berte, F.: Occurence of alpha- and beta-receptors in the bile duct. Proc. Soc. exp. Biol. (N. Y.) 120, 158–160 (1965).Google Scholar
  114. Cumming, G. R.: Propranolol in tetralogy of fallot. Circulation 41, 13–15 (1970).PubMedGoogle Scholar
  115. Cumming, G. R., Carr, W.: Relief of dyspneic attacks in Fallot’s tetralogy with propranolol. Lancet 19001 a, 519–522.Google Scholar
  116. Cumming, G. R., Carr, W.: Hemodynamic response to exercise after beta-adrenergic blockade with propranolol in patients with mitral valve obstruction. Canad. med. Ass. J. 95, 527 (1966b).Google Scholar
  117. Cumming, G. R., Carr, W.: Hemodynamic response to exercise after propranolol in normal subjects. Canad. J. Physiol. Pharmacol. 44, 465–474 (1966 c).Google Scholar
  118. Cumming, G. R., Carr, W.: Hemodynamic response to exercise after beta-adrenergic and parasympathetic blockade. Canad. J. Physiol. Pharmacol. 45, 813–819 (1967a).Google Scholar
  119. Cumming, G. R., Carr, W.: Hemodynamic effects of propranolol in patients with Fallot’s tetralogy. Amer. Heart. J. 74, 29–36 (1967b).PubMedGoogle Scholar
  120. Dale, H. H.: On some physiological actions of ergot. J. Physiol. (Lond.) 34, 163–206 (1906).Google Scholar
  121. Dallavalle, L., Botti, G., Yisioli, O.: Primi risultati della sperimentazione clinica pianificata nell’angina di petto di un farmaco ad azione bloccante beta-adrenergica. Clin. ter. 83, 523–529 (1965).Google Scholar
  122. Darsinos, J., Katsilambros, N., Papamatheon, M., Papadoyanakis, N.: The response of thyrotoxic tachycardia to Trasicor, a new beta-adrenergic blocking agent. Curr. ther. Res. 10, 626–630 (1968).PubMedGoogle Scholar
  123. Davis, L. D., Temte, Y. V.: Effects of propranolol on the transmembrane potentials of ventricular muscle and Purkinje fibers of the dog. Circulat. Res. 22, 661–677 (1968).PubMedGoogle Scholar
  124. De Divitiis, O., Giordano, F., Gallo, B., Jacono, A.: Tolbutamide and propranolol. Lancet 1908 I, 749.Google Scholar
  125. Delius, W.: Beobachtungen über die Wirkung eines β-Rezeptorenblockers bei vegetativen Herz- und Kreislaufstörungen. Med. Klin. 02, 1128–1136 (1967).Google Scholar
  126. Diamond, G., Brody, Th. M.: Hormonal alteration of the responses of the rat uterus to catecholamines. Life Sei. 5, 2187–2193 (1966).Google Scholar
  127. Dienstl, F., Gmeiner, R., Meirer, R.: Medikamentöse Blockade adrenerger β-Rezeptoren bei Rhythmusstörungen. Wien. klin. Wschr. 79, 329–332 (1967).Google Scholar
  128. Dienstl, F., Gmeiner, R., Raas, R.: Veränderungen des Mechanocardiogramms und des Blutdruckes durch Adrenalin vor und nach Blockade adrenergischer β-Rezeptoren. Klin. Wschr. 44, 41–44 (1966).PubMedGoogle Scholar
  129. Dittrich, P., Dienstl, F., Gmeiner, R.: On the question of adrenergic control of renal circulation. Wien. klin. Wschr. 78, 424–425 (1966).Google Scholar
  130. Donoso, E., Cohn, L. J., Newman, B. J., Bloom, H. S., Stein, W. G., Friedberg, C. K.: Effects of propranolol on patients with complete heart block and implanted pacemakers. Circulation 36, 534–538 (1967).PubMedGoogle Scholar
  131. Dorigotti, L., Gaetani, M., Glässer, A. H., Rutolla, E.: Competitive antagonism of isoprenaline-induced cardiac necroses by β-adrenoreceptor blocking agents. J. Pharm. Pharmacol. 21, 188–191 (1969).PubMedGoogle Scholar
  132. Dornhorst, A. C., Laurence, D. R.: Use of pronethalol in phaeochrome tumours. Brit. med. J. 1963II, 1250–1251.Google Scholar
  133. Doutheil, U., Ten Bruggencate, H. G., Kramer, K.: Wirkung von Katecholaminen auf die Coronardurchblutung, Herzfrequenz und 02-Verbrauch nach Blockierung der β-Rezeptoren durch Nethalide (2-isopropylamino-l-(2-naphtyl) äthanol-hydrochlorid). Pflügers Arch. ges. Physiol. 279, R 12 (1964).Google Scholar
  134. Dreifus, L. S., Lim, H. F., Watanabe, Y., Mc Knight, E.. Frank, M. K: Propranolol and quinidine in the management of ventricular tachycardia. J. Amer. med. Ass. 204, 736 bis 737 (1968).Google Scholar
  135. Duce, B. R., Garberg, L., Johansson, B.: The effect of propranolol and the dextro and laevo isomers of H 56–28 upon ouabain induced ventricular tachycardia in unanaesthe- tized dogs. Acta pharmacol. (Kbh.) 25, 41–49 (1967).Google Scholar
  136. Duchêne-Marullaz, P., Schaff, G., Lautier, F., Lawarenne, J.: Effet dromotrope négatif du propranolol. Thérapie 22, 1079–1081 (1967).PubMedGoogle Scholar
  137. Dunlop, D., Shanks, R. G.: Selective blockade of adrenoceptive beta receptors in the heart. Brit. J. Pharmacol. 82, 201–218 (1968).Google Scholar
  138. Dwyer, E. M. Jr., Wiener, L.,Cox, J. W.: Effects of beta-adrenergic blockade (propranolol) on left ventricular haemodynamics and the electrocardiogram during exercise-induced angina pectoris. Circulation 38, 250–260 (1968).Google Scholar
  139. Eckstein, J. W., Wendling, M. G., Abboud, F. M.: Forearm venous responses to stimulation of adrenergic receptors. Circulation 30, Suppl. Ill, 71 (1964).Google Scholar
  140. Eggstein, M.: Die Substrat- und Metabolitverschiebungen im Blut nach Adrenalin und ß-Rezeptorenblockern. Betarezeptorenblockade in Klinik und Experiment. Wien: Hollinek, 1968.Google Scholar
  141. Ehrlich, P.: Ansprache bei der Einweihung des Georg-Speyer-Hauses: Himmelweit, F.: The collected papers of Paul Ehrlich, Vol. III. Pergamon Press Ltd. London: 1960.Google Scholar
  142. Eiff, A. W. von, Czernik, A., Zanders, K.: Zur medikamentösen Beeinflussung der Sym- pathicushyperaktivität. Parasympathicomimeticum und Beta-Rezeptorenblocker im kurz-dauernden pharmakologischen Experiment am Menschen. Klin. Wschr. 47, 701–708 (1969).Google Scholar
  143. Eisenfeld, A. G., Krakoff, L., Iversen, L. L., Axelrod, J.: Inhibition of the extraneural metabolism of noradrenaline in the isolated heart by adrenergic blocking agents. Nature (Lond.) 213, 297–298 (1967).Google Scholar
  144. Eliasch, H., Rosen, A., Scott, H. M.: Beta-adrenergic receptor blockade and plasma catecholamine determination as aids in the analysis of the origins of the hemodynamic response to link trainer simulated flight. Circulation 32, 81–82 (1965).Google Scholar
  145. Eliasch, H., Rosen, A., Scott, H. M.: Systemic circulatory response to stress of simulated flight and to physical exercise before and after propranolol blockade. Brit. Heart J. 29, 671–683 (1967).PubMedGoogle Scholar
  146. Elliott, J., Black, G. W., McCullough, H.: Catecholamine and acid-base changes during anaesthesia and their influence upon the action of propranolol. Brit. J. Anaesth. 40, 615–623 (1968).PubMedGoogle Scholar
  147. Entman, M. L., Martin, A. M., Jr., Mikat, E. M., Bourianoff, G. G., Hackel, D. B.: Effects of beta-sympathetic blockade on coronary blood flow in hemorrhagic shock in dogs. Circulation 32, Suppl. II, 82 (1965).Google Scholar
  148. Entman, M. L., Martin, A. M., Jr., Mikat, E. M., Chang, J. H. T., Hackel, D. B.: Phasic myocardial blood flow in hemorrhagic hypotension. Amer. J. Cardiol. 21, 881–885 (1968).PubMedGoogle Scholar
  149. Epstein, S. E., Braunwald, E.: Beta-adrenergic receptor blocking drugs. New Engl. J. Med. 275, 1106–1112, 1175–1183, (1966a).Google Scholar
  150. Epstein, S. E., Braunwald, E.: The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Ann. int. Med. 65, 20–27 (1966b).PubMedGoogle Scholar
  151. Epstein, S. E., Robinson, B. F., Kahler, R. L., Brattnwald, E.: Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J. clin. Invest. 44, 1745–1753 (1965).PubMedGoogle Scholar
  152. Erlij, D., Mendez, R.: The modification of digitalis intoxication by excluding adrenergic influences on the heart. J. Pharmacol. 144, 97–103 (1964).Google Scholar
  153. Estler, C. J., Strubelt, O., Ammon, H. P. T.: The effect of adrenergic beta-block on thermo-regulation in acute exposure to cold. Pflügers Arch. ges. Physiol. 289, 227–236 (1966).Google Scholar
  154. Fain, J. F.: Adrenergic blockade of hormone-induced lipolysis in isolated fat cells. Ann. N. Y. Acad. Sei. 189, 879–890 (1967).Google Scholar
  155. Fantini, F., Berni, G., Brat, A.: Observations on the pathogenesis of the cardiovascular manifestations of hyperthyroidism: Effect of beta-receptor blocking drugs. Studi sassaresi 1 /2, 194 (1966).Google Scholar
  156. Farmer, J. B., Levy, G. P.: A comparison of some cardiovascular properties of propranolol MJ 1999 and quinidine in relation to their effects in hypertensive animals. Brit. J. Pharmacol. 34, 116–126 (1968).Google Scholar
  157. Fawar, G.: Effect of reserpine and pronethalol on the therapeutic and toxic actions of digitalis in the dog heart-lung preparation. Brit. J. Pharmacol. 29, 302–308 (1967).Google Scholar
  158. Fearon, R. E.: Propranolol in the prevention of ventricular fibrillation due to experimental coronary artery occlusion. Observations on its mode of action. Amer. J. Cardiol. 20, 222–228 (1967).PubMedGoogle Scholar
  159. Ferrari, G., Casagrande, C., Canova, M.: Una nuova servie di inibitori dei recettori beta-adrenergic. Boll. chim. farm. 103, 32 (1964).PubMedGoogle Scholar
  160. Ferrini, R., Miragoli, G., Croce, G.: The pharmacological actions of butidrine. A com-parative study of this new β-adrenergic receptor antagonist and its four stereoisomers. Arzneimittel-Forsch. 18, 829–833 (1968).Google Scholar
  161. Fewings, J. D.: Catecholamine stores and the negative inotropic effect of beta-adrenergic blocking agents in post-exercise hyperaemia in man. Aust. J. exp. Biol. med. Sei. 45, 347–354 (1967).Google Scholar
  162. Fiene, T. J., Griffin, J. R., Harrison, D. C.: Beta-adrenergic blockade with propranolol in atrial arrhythmias. Circulation 32, Suppl. II, 84 (1965).Google Scholar
  163. Finlay, W. E., Dykes, W. S.: Cardiac arrhythmia during hypothermia controlled by pro-pranolol. Anaesthesia 23, 631–635 (1968).PubMedGoogle Scholar
  164. Fitzgerald, J. D.: Inderal in angina pectoris. Wien. klin. Wschr. 79, 332–336 (1967 a).Google Scholar
  165. Fitzgerald, J. D.: Propranolol-induced depression. Brit. med. J. 1967 lib, 372–373.Google Scholar
  166. Fitzgerald, J. D., Scales, B.: Effect of a new adrenergic beta-blocking agent (ICI 50,172) on heart rate in relation to its blood levels. Int. Z. klin. Pharmakol. Ther. Toxikol. 1, 467–474 (1968).PubMedGoogle Scholar
  167. Fleckenstein, A., Döring, H. J., Kammermeier, H.: Einfluß von Beta-Receptorenblockern und verwandten Substanzen auf Erregung, Kontraktion und Energiestoffwechsel der Myokardfaser. Klin. Wschr. 46, 343–351 (1968).PubMedGoogle Scholar
  168. Fleckenstein, A., Döring, H. J., Döring, H. J.: Zum Wirkungsmechanismus neuartiger Koronardilatatoren mit gleichzeitig Sauerstofif-einsparenden Myokardeffekten, Prenylamin und Iproveratril. Z. Kreisl.- Forsch. 56, 716–744, 839–858 (1967).Google Scholar
  169. Forsberg, S. A., Johnsson, G.: Hemodynamic effects of propranolol and H 56/28 in man. A comparative study of two beta-adrenergic receptor antagonists. Life Sei. 6, 1147–1154 (1967).Google Scholar
  170. Forster, R.: Behandlung endokriner Krisen. Ther. d. Gegenw. 106, 316–327 (1967).Google Scholar
  171. Fowler, N. O., Holmes, J. C., Gaffney, T. E.: Beta-sympathetic blockade and the hemo-dynamic effects of anemia. Circulation 36, Suppl. II, 111 (1967).Google Scholar
  172. Frankl, W. S., Soloff, L. A.: Sotalol: A new, safe beta adrenergic receptor blocking agent. Amer. J. Cardiol., 22, 266–272 (1968).PubMedGoogle Scholar
  173. Fratz, R., Greeff, K., Wagner, J.: Über den Einfluß der β-Rezeptorenblocker, des Iproveratrils, Chinidins und Reserpins auf die Wirkung des k-Strophantins am Meerschweinchenherzen. Naunyn-Schmiedebergs Areh.-Pharmak. exp. Path. 256, 196–206 (1967).Google Scholar
  174. Freundt, K. J.: Adrenergic alpha- and beta-receptors in the mouse iris. Nature (Lond.) 206, 725–726 (1965).Google Scholar
  175. Frieden, J.: Propranolol as an antiarrhythmic agent. Amer. Heart J. 74, 283–285 (1967a).PubMedGoogle Scholar
  176. Frieden, J.: Propranolol in the treatment of angina pectoris. Amer. Heart J. 74, 431–433 (1967 b).Google Scholar
  177. Froer, K.-L., König, E., Grünberg, G.: Belastungsinsuffizienz des Herzens durch beta- rezeptorenblockierende Substanzen. Med. Klin. 64, 1663–1668 (1969).PubMedGoogle Scholar
  178. Fröhlich, E. D., Dttstan, H. P., Page, I. H.: Hyperdynamic beta-adrenergic circulatory state. Arch, intern. Med. 117, 614–619 (1966).Google Scholar
  179. Fröhlich, E. D., Tarazi, R. C., Dustan, H. P., Page, I. H.: The paradox of beta-adrenergic blockade in hypertension. Circulation 37, 417 - 423 (1968).PubMedGoogle Scholar
  180. Fröhlich, E. D., Tarazi, R. C., Dustan, H. P.: Peripheral arterial insufficiency. J. Amer. med. Ass. 208, 2471–2472 (1969).Google Scholar
  181. Fukushima, K., Fujita, T., Fujiwara, T., Ooshima, H., Sato, T.: Effect of propranolol on the ventricular arrhythmias induced by hypercarbia during halothane anaesthesia in man. Brit. J. Anaesth. 40, 53–58 (1968).PubMedGoogle Scholar
  182. Furberg, C.: Adrenergic beta-blockade and electrocardiographical ST-T changes. Acta med. scand. 181, 21–32 (1967a).PubMedGoogle Scholar
  183. Furberg, C.: Adrenergic beta-blockade and physical working capacity. Acta med. scand. 182, 119–127 (1967b).PubMedGoogle Scholar
  184. Furberg, C.: Adrenergic beta-receptor blockade and the relationships between physical working capacity, heart volume, and the total amount of hemoglobin. Scand. J. clin. Lab. Invest. 19, 164 (1967 c).Google Scholar
  185. Furberg, C., Jacobsson, K. A.: Propranolol and angina pectoris. An analysis of the different responses to the drug in patients with angina pectoris. Acta med. scand. 181, 729–736 (1967).PubMedGoogle Scholar
  186. Furberg, C., Morsing, C.: Adrenergic beta-receptor blockade in neurocirculatory asthenia. Pharmacol. Clin. 1, 168–171 (1969).Google Scholar
  187. Furberg, C., Tengblad, C. F.: Adrenergic beta-receptor blockade and the effect of hyperventilation on the electrocardiogram. Scand. J. clin. Lab. Invest. 18, 467–472 (1966).PubMedGoogle Scholar
  188. Furchgott, R. F.: The pharmacological differentiation of adrenergic receptors. Ann. N. Y. Acad. Sei. 139, 553–570 (1967).Google Scholar
  189. Gabor, G.: The effect of beta-receptor blocking agent on various cardiac arrhythmias. Münch, med. Wschr. 109, 195–199 (1967).Google Scholar
  190. Garnier, B., Imhof, P.: Effect of beta-receptor blockade on circulatory function test (ortho-static test, Valsalva’s test, vasopressin test). Cardiologia (Basel) 49, 146–148 (1966).Google Scholar
  191. Gattenlöhner, W., Schneider, K. W., Kost, R.: Betarezeptorenblocker beim hyperzirkulatorischen Syndrom und beim Leistungssportler. Med. Welt 42, 2298–2306 (1969).PubMedGoogle Scholar
  192. Gebbie, D. M., Finlayson, D. C.: Use of alpha and beta adrenergic blocking drugs and halothane in the anaesthetic management of pheochromocytoma. Canad. Anaesth. Soc. J. 14, 39–43 (1967).PubMedGoogle Scholar
  193. Gebhardt, W., Reindell, H., König, K., Büchner, Ch.: Herz- und Kreislaufdynamik nach medikamentöser Beta-Rezeptoren-Blockade. Verh. dtsch. Ges. Kreisl.-Forsch. 31, 99–107 (1965).Google Scholar
  194. Gebhardt, W., Wegener, M., Zix, R., Klemm, D., Büchner, Ch., Reindell, H.: Therapeutische Erfahrungen bei der Behandlung hypertoner Kreislaufregulationsstörungen mit Inderal. Wien. klin. Wschr. 79, 337–342 (1967).PubMedGoogle Scholar
  195. Gedeon, A.: Propranolol in myocardial infarction. Brit. med. J. 1908 III, 619–620.Google Scholar
  196. Gersmeyer, E. F., Beyer, E., Leicht, E., Spitzbarth, H.: Herz- und Kreislaufdynamik des Hundes unter Wirkung des beta-Rezeptorenblockers Propranolol. Z. ges. exp. Med. 143, 85–96 (1967).Google Scholar
  197. Gettes, L. S., Stjrawicz, B.: Long term prevention of paroxysmal arrhythmias with pro-pranolol therapy. Amer. J. med. Sei. 254, 257–265 (1967).Google Scholar
  198. Gianelly, R., Goldman, R. H., Treister, B., Harrison, D. C.: Propranolol in patients with angina pectoris. Ann. intern. Med. 67, 1216–1225 (1967b).PubMedGoogle Scholar
  199. Gianelly, R., Griffin, J. R., Harrison, D. C.: Propranolol in the treatment and prevention of cardiac arrhythmias. Ann. intern. Med. 66, 667–676 (1967a).PubMedGoogle Scholar
  200. Gibson, D., Sowton, E.: Effects of ICI 50172 in man during erect exercise. Brit. med. J. 19681, 213–215.Google Scholar
  201. Gilbert-Dreyfus, G., Delzant, G., Sebaoun, G., Schaison, G., Benveniste, J.: Utilisation des jft-bloquants dans les thyrotoxicoses et au cours du traitement des insuffisances thyro- idiennes. Ann. Endocr. (Paris) 28, 686–692 (1967).Google Scholar
  202. Gilfrich, H. J., Rahn, K. H., Schmahl, F. W.: Untersuchungen über die antihypertensive Wirkung von Beta-Receptoren blockierenden Substanzen. Verh. dtsch. Ges. inn. Med. 74, 562–565 (1968).PubMedGoogle Scholar
  203. Gillam, P. M. S., Prichard, B. N. C.: Use of propranolol in angina pectoris. Brit. med. J. 1965 II, 337–339.Google Scholar
  204. Gillam, P. M. S., Prichard, B. N. C.: Propranolol in the therapy of angina pectoris. Amer. J. Cardiol. 18, 366–369 (1966).PubMedGoogle Scholar
  205. Ginn, W. M., Irons, G. V., Orgain, E. S.: Use of propranolol in cardiac arrhythmias. Circulation 32, 97–98 (1965).Google Scholar
  206. Ginn, W. M., Jr., Orgain, E. S.: Propranolol hydrochloride in the treatment of angina pectoris J. Amer. med. Ass. 198, 1214–1216 (1966).Google Scholar
  207. Giudicelli, J. F., Schmitt, H., Biossier, J. R.: Studies on dl-4-(2-hydroxy-3-isopropyl- aminopropoxy)-indole (LB 46), a new potent beta adrenergic blocking drug. J. Pharmacol, exp. Ther. 168, 116–126 (1969).Google Scholar
  208. Glick, G., Parmley, W. W., Wechsler, A. S., Sonnenblick, E. H.: Glucagon. Its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol. Circulat. Res. 22, 789–799 (1968).PubMedGoogle Scholar
  209. Glover, W. E., Hutchison, K. J.: The effect of a beta receptor antagonist (propranolol) on the cardiovascular response to intravenous infusions of noradrenaline in man. J. Physiol. 177, 59–60 (1965).Google Scholar
  210. Gmeiner, R., Dienstl, F.: Zur Wirkung von Adrenalin auf Herz und Kreislauf nach β-Blockade. Klin. Wschr. 44, 764–766 (1966).PubMedGoogle Scholar
  211. Goldstein, S., Killip, T.: Catecholamine depletion in thyrotoxicosis. Effect of guanethedine on cardiovascular dynamics. Circulation 31, 219–227 (1965).PubMedGoogle Scholar
  212. Gorlin, R.: The hyperkinetic heart syndrome. J. Amer. med. Ass. 182, 823–829 (1962).Google Scholar
  213. Gorlin, R., Brachfeld, N., Turner, J. D., Messer, J. V., Salazar, E.: The idiopathic high cardiac output state. J. clin. Invest. 38, 2144–2153 (1959).PubMedGoogle Scholar
  214. Govier, W. C., Mosal, N. C., Whittington, P., Broom, A. H.: Myocardial alpha and beta adrenergic receptors as demonstrated by atrial functional refractory period changes. J. Pharmacol, exp. Ther. 154, 255–263 (1966).Google Scholar
  215. Graf, K.: Distensibility of low-pressure capacitance blood vessels of the forearm in patients with vasoregulatory asthenia. Z. ges. exp. Med. 140, 113–127 (1966).Google Scholar
  216. Graf, K., Ström G.: Circulatory and psychophysiological reactions to adrenalin and noradrenalin in patients with vasoregulatory asthenia. Z. ges. exp. Med. 140, 91–112 (1966).Google Scholar
  217. Graf, K., Ström G.: Blood flow in extremities at rest in patients with vasoregulatory asthenia (hyperkinetic circulation and low physical work capacity). Arch. Kreisl.-Forsch. 50, 231–250 (1966).Google Scholar
  218. Graf, K., Ström G.: Circulation reactions in the forearm and hand during and after exercise in patients with vasoregulatory asthenia. Arch. Kreisl.-Forsch. 50, 251–270 (1966).Google Scholar
  219. Grandjean, T.: Les effets aigus des bloqueurs adrénergiques-β. Schweiz, med. Wschr. 97, 1559–1564 (1967).Google Scholar
  220. Grandjean, T., Hamer, N. J., Sowton, G. E., Melendez, L.: Effect of propranolol (Inderal), a new specific blocking agent of adrenergic beta- receptors on effort tolerance in angina pectoris. Cardiología (Basel) 48, 369–370 (1966a).Google Scholar
  221. Grandjean, T., Rivier, J. L.: Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and Ciba 39, 089-Ba. Brit. Heart J. 30, 50–59 (1968).PubMedGoogle Scholar
  222. Grant, R. H. E, Green, K. G.: Propranolol. Lancet 1964 II, 1240–1241.Google Scholar
  223. Grant, R. H. E, Keelan, P., Kernohan, R. J., Leonad, J. C., Nancekievill, L., Sinclair, K.: Multicenter trial of propranolol in angina pectoris. Amer. J. Cardiol. 18, 361–365 (1966).PubMedGoogle Scholar
  224. Granville-Grossman, K. L., Turner, P.: The effect of propranolol on anxiety. Lancet 1966 I, 788–790.Google Scholar
  225. Grayson, G.: Propranolol in myocardial infarction. Lancet 1967 I, 788–789.Google Scholar
  226. Greeff, K., Wagner, J.: Hemmung der Monoaminoxydase durch ß-adrenolytisch wirksame Substanzen. Naturwissenschaften 53, 40 (1966).PubMedGoogle Scholar
  227. Hadden, D. R., Montgomery, D. A. D., Shanks, R. G., Weaver, G. A.: Propranolol and iodine-131 in the management of thyrotoxicosis. Lancet 1968 II, 852–854.Google Scholar
  228. Hadjiyanni, B., Kaindl, F., Ogris-Kauteke, E., Steinbach, K.: On influencing the pressure gradient in subaortic stenosis using beta-receptor blocking agents. Wien. klin. Wschr. 79, 342–343 (1967).PubMedGoogle Scholar
  229. Haefely, W., Mürlimann, A., Thoenen, H.: Some pharmacological actions of the β-adrenolytic agent R»o 3-3528 (6,7-dimethyl-a-[(isopropylamino)methyl]-2-benzofuranmethanol- hydrochloride). Angiologica 4, 203–215 (1967).PubMedGoogle Scholar
  230. Hahn, R. A., Pendleton, R. G., Wardell, J. R. Jr.: A comparative study of the beta adrenergic blocking activities of propranolol and INPEA. J. Pharmcol. exp. Ther. 161, 111–121 (1968).Google Scholar
  231. Halmagyi, D. F., Irving, M. H., Gilett, D. G., Varga, D.: Effect of adrenergic blockade on consequences of substained epinephrine infusion. J. appl. Physiol. 23, 171–177 (1967).PubMedGoogle Scholar
  232. Hamer, J., Fleming, W.: Effect of propranolol on left ventricular work in aortic stenosis. Brit. Heart. J. 29, 871–882 (1967).PubMedGoogle Scholar
  233. Hamer, J., Grandjean, T., Melendez, L., Sowton, G. E.: Effect of propranolol (Inderal) on exercise tolerance in angina pectoris. Brit. Heart J. 28, 414–418 (1966).PubMedGoogle Scholar
  234. Hamer, J., Melendez, L., Sowton, E.: Propranolol for angina. Brit. med. J. 1964 II, 1136.Google Scholar
  235. Hamer, J., Sowton, E.: Cardiac output after beta-adrenergic blockade in ischaemic heart disease. Brit. Heart J. 27, 892–895 (1965).PubMedGoogle Scholar
  236. Hamer, J., Sowton, E.: Effects of propranolol on exercise tolerance in angina pectoris. Amer. J. Cardiol. 18, 354–360 (1966).PubMedGoogle Scholar
  237. Hamm, J., Hunekohl, E., Schmidt, A.: Wirkungen eines adrenergischen Beta-Receptoren- blockers (Kö 592) auf die Atmung. Klin. Wschr. 8, 457–464 (1970).Google Scholar
  238. Harris, A.: Long term treatment of paroxysmal cardiac arrhythmias with propranolol. Amer. J. Cardiol. 18, 431 - 437 (1966a).PubMedGoogle Scholar
  239. Harris, W. S.: Excessive cardiac adrenergic activity: cause of a hyperkinetic circulatory state in psychotic patients (P). Circulation 34, Suppl. III, 123 (1966b).Google Scholar
  240. Harris, W. S., Schoenfeld, C. D., Gwynne, P. H., Weissler, A. M., Warren, J. V.: Observations on the cardiovascular response to fear and anger. Circulation 30, Suppl. III, 92–93 (1964).Google Scholar
  241. Harris, W. S., Schoenfeld, C. D., Weissler, A. M., Brooks, R. H.: Beta component in circulatory actions of norepine-phrine in man. Circulation 32, Suppl. II, 107 (1965a).Google Scholar
  242. Harris, W. S., Schoenfeld, C. D., Weissler, A. M., Brooks, R. H.: The detection of adrenergic influences on the human left ventricle. Clin. Res. 13, 401 (1965b).Google Scholar
  243. Harris, W. S., Schoenfeld, C. D., Weissler, A. M., Brooks, R. H.: Effects of adrenergic receptor activation and blockade on the systolic preejection period, heart rate, and arterial pressure in man. J. clin. Invest. 40, 1704 (1967).Google Scholar
  244. Harris, W. S., Weissler, A. M.: Use of beta-adrenergic blockade to assess cardiac sympathetic activity in man. Circulation 30, Suppl. Ill, 93 (1964).Google Scholar
  245. Harrison, D. C., Bratjnwald, E., Glick, G., Mason, D. T., Chidsey, C. A., Ross, J., Jr.: Effects of beta-adrenergic blockade on the circulation, with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 29, 84–98 (1964).PubMedGoogle Scholar
  246. Harrison, D. C., Chidsey, C. A.: Cardioaccelerator nerve stimulation and pronethalol on metabolism of norepinephrine. Amer. J. Physiol. 210, 1369–1374 (1966).PubMedGoogle Scholar
  247. Harrison, D. C., Griffin, J. R.: Metabolic and circulatory responses to selective adrenergic stimulation and blockade. Circulation 34, 218–225 (1966).PubMedGoogle Scholar
  248. Harrison, D. C., Griffin, J. R.: The antiarrhythmic effects of propranolol. Ann. N. Y. Acad. Sei. 139, 997–1002 (1967).Google Scholar
  249. Harrison, D. C., Griffin, J. R., Fiene, T. J.: Effects of beta-adrenergic blockade with propranolol in patients with atrial arrhythmias. New Engl. J. Med. 273, 410–415 (1965).PubMedGoogle Scholar
  250. Hashimoto, K., Matsumura, S., Sano, N., Taira, N.: Comparison of ß-adrenergic blocking activity of dichloroisoprenaline (H 56 /28, I. C.I. 50172, LB 46), methoxamine (MJ 1999) and propranolol in the canine femoral vascular bed. Experientia (Basel)25, 1155–1156 (1969a).Google Scholar
  251. Hashimoto, K., Ohkttda, K., Chiba, S., Taira, N.: Beta-adrenergic blocking effect of dichloroisoprenaline (DCI), (H 56/28, ICI 50172, LB 46), methoxamine (MJ 1999) and propranolol on the sinus node activity of the dog heart. Experientia (Basel) 25, 1156–1157 (1969b).Google Scholar
  252. Hashimoto, Y., Lydtin, H.: Effect of DOPA on the catecholamine content of dog heart after hemorrhagic hypotension. Jap. J. Pharmacol. 15, 401–415 (1965).PubMedGoogle Scholar
  253. Hebb, A. R., Godwin, T. F., Gunton, R. W.: A new beta-adrenergic blocking agent, pro-pranolol, in the treatment of angina pectoris. Canad. med. Ass. J. 98, 246–251 (1968).Google Scholar
  254. Hegglin, R., Krayenbühl, H. P., Lüthy, E.: Der Einfluß eines β-Rezeptorenblockers (Nethalide) auf einige Parameter der Kreislaufdyn amik. Z. ges. exp. Med. 138, 141–149 (1964).PubMedGoogle Scholar
  255. Heidenreich, O., Laaft, H., Fülgraft, G., Balshüsemann, E.: Die Wirkungen von Orci- prenalin, Isoprenalin und Propranolol auf die Nierenfunktion des Hundes. Naunyn- Schmiedebergs Arch.-Pharmak. exp. Path. 255, 23–24 (1966).Google Scholar
  256. Heim, T., Hull, D.: The effect of propranolol in the calorigenic response in brown adipose tissue of new-born rabbits to catecholamines, glucagon, corticotropin and cold exposure. J. Physiol (Lond.) 187, 271–283 (1966).Google Scholar
  257. Hellewell, J., Potts, M. W.: Propranolol and ventricular arrhythmias with halothane. Anaesthesia 20, 269 (1965).Google Scholar
  258. Hermansen, K.: Anti-arrhythmic and local anaesthetic activity of some beta-receptor blocking compounds. Brit. J. Pharmacol. 34, 200–201 (1968).Google Scholar
  259. Herring, A. B.: Action of pronethalol on parkinsonian tremor. Lancet 1964II, 892.Google Scholar
  260. Herxheimer, H., Lakger, I.: Untersuchungen über die bronchokonstriktorische Wirkung des β-Rezeptorblockers Propranolol bei Meerschweinchen und Patienten mit Asthma bronchiale. Klin. Wschr. 45, 1149–1153 (1967).PubMedGoogle Scholar
  261. Hess, M. L., Briggs, F. N., Shinebotjrne, E., Hamer, J.: Effect of adrenergic blocking agents on the calcium pump of the fragmented cardiac sarcoplasmic reticulum. Nature (Lond.) 220, 79–80 (1968).Google Scholar
  262. Hewitt, P. B., Lord, P. W., Thornton, H. L.: Propranolol in hypotensive anaesthesia. Anaesthesia 22, 82–89 (1967).PubMedGoogle Scholar
  263. Hill, A. J., Kohli, J. D.: Adrenoceptive receptors in the duodenum, aorta and atria of the rabbit. J. Pharm. Pharmacol. 19, 350–354 (1967).PubMedGoogle Scholar
  264. Hill, R. C., Turner, P.: The effects of a new beta-adrenoceptive receptor blocking drug on heart rate in man. Brit. J. Pharmacol. 82, 663–670 (1968).Google Scholar
  265. Hill, R. C., Turner, P.: Preliminary investigations of a new beta-adrenoceptive receptor blocking drug, LB 46, in man. Brit. J. Pharmacol. 36, 368–372 (1969).Google Scholar
  266. Hilmi, K. I., Regan, T. J.: Relative effectiveness of antiarrhythmic drugs in treatment of digitalis-induced ventricular tachycardia. Amer. Heart J. 76, 365–369 (1968).PubMedGoogle Scholar
  267. Himms-Hagen, J.: Sympathetic regulation of metabolism. Pharmacol. Rev. 19, 367–461 (1967).PubMedGoogle Scholar
  268. Hirche, H. J.: Die Wirkung von Isoproterenol, Adrenalin, Noradrenalin und Adenosin auf die Durchblutung und den 02-Verbrauch des Herzmuskels vor und nach der Blockierung der β-Rezeptoren. Pflügers Arch. ges. Physiol. 288, 163–185 (1966).Google Scholar
  269. Hirvonen, L., Paavilainen, F. O. A.: Response of rat atrium to propranolol and catecholamines in various states of thyroid action. Acta physiol. scand. 69, 284–294 (1967).PubMedGoogle Scholar
  270. Höfer, R., Keminger, K., Kraupp, O., Seidl, H., Steinbereithner, K.: Zur prä- und postoperativen Behandlung schwerer Hyperthyreosen mit Propranolol. Wien. med. Wschr. 119, 89–94 (1969).PubMedGoogle Scholar
  271. Hoffman, B. F., Singer, D. H.: Appraisal of the effects of catecholamines on cardiac electrical activity. Ann. N. Y. Acad. Sei. 139, 914–939 (1967).Google Scholar
  272. Holmberg, G., Levi, L., Nathé, A., Rosen, A., Scott, H. M.: Comparison of the plasma catecholamine levels and the influence of propranolol on peripheral hemodynamic mani-festations of emotional stress in labile hypertensive and normal subjects. Circulation 32, Suppl. II, 115 (1965).Google Scholar
  273. Holmgren, A., Jonsson, B., Levander, M., Linderholm, H., Sjöstrand,T., Ström, G.: Low physical working capacity in suspected heart cases due to inadequate adjustment of peripheral blood flow (Vasoregulatory asthenia). Acta med. scand. 163, 413 (1957).Google Scholar
  274. Honey, M., Chamberlain, D. A., Howard, J.: The effect of beta-sympathetic blockade on arterial oxygen saturation in Fallot’s tetralogy. Circulation 30, 501–510 (1964).PubMedGoogle Scholar
  275. Honig, C. R., Stam, A. C., Jr.: The influence of adrenergic mediators and their structural analogs on cardiac actomyosin systems. Ann. N. Y. Acad. Sei. 139, 724–740 (1967).Google Scholar
  276. Howe, R.: Carcinogenicity of „alderlin“(pronethalol) in mice. Nature (Lond.) 207, 594–595 (1965).Google Scholar
  277. Howe, R., Shanks, R. G.: Optical isomers of propranolol. Nature (Lond.) 210, 1336 (1966).Google Scholar
  278. Howitt, G., Rowlands, D. J.: Beta-sympathetic blockade in hyperthyroidism. Lancet 1966 I, 628–631.Google Scholar
  279. Hughes, G.: Management of thyrotoxic crises with a beta-adrenergic blocking agent (pronethalol). Brit. J. clin. Pract. 20, 579–581 (1966).PubMedGoogle Scholar
  280. Humphreys, G. S.: Digitalis intoxication. Practitioner 198, 256–263 (1967).PubMedGoogle Scholar
  281. Humphreys, G. S., Pelvin, D. G.: Ineffectiveness of propranolol in hypertensive jamaicans. Brit. med. J. 1968 II, 601–603.Google Scholar
  282. Hunninghake, D. B., Azarnoff, D. L., Waxman, D.: Drug inhibition of catecholamine-induced, metabolic effects in humans. Ann. N. Y. Acad. Sei. 139, 971–980 (1967).Google Scholar
  283. Ikram, H.: Propranolol in persistent ventricular fibrillation complicating acute myocardial infarction. Amer. Heart. J. 75, 795–798 (1968).PubMedGoogle Scholar
  284. Irons, G. V., Ginn, W. N., Orgain, E. S.: Use of a beta-adrenergic receptor blocking agent (propranolol) in the treatment of cardiac arrhythmias. Amer. J. Med. 43, 161–170 (1967).PubMedGoogle Scholar
  285. Iwatsuki, K., Yusa, T., Hashimoto, Y., Watabe, Y.: Effect of propranolol on paroxysmal ventricular fibrillation. Tohoku J. exp. Med. 88, 257–262 (1966a).Google Scholar
  286. Iwatsuki, K., Yusa, T., Yasuda, I., Hashimoto, Y., Takahashi, K., Iwatsuki, N.: Effect of propranolol on cardiac arrhythmias induced by adrenaline under halothane anesthesia. Tohoku J. exp. Med. 88, 263–276 (1966b).Google Scholar
  287. Iwatsuki, K., Yusa, T., Yasuda, I., Hashimoto, Y., Takahashi, K., Iwatsuki, N.: Effect of propranolol on cardiac arrhythmias induced by adrenaline under halothane anesthesia. Tohoku J. exp. Med. 88, 263 (1966 c).Google Scholar
  288. Jacobi, H.: Inhibition of tremor by active beta-adrenolytic substances. Naturwissenschaften 54, 94 (1967).PubMedGoogle Scholar
  289. Januszewicz, W., Sznajderman, M., Poplawska, W.: Ocena wartosci propranololu w leczeniu choroby wiencowej. Pol. Arch. Med. wewnet. 36, 777–781 (1966).PubMedGoogle Scholar
  290. Jaquenoud, P.: 2-Prevention par le propranolol de certains troubles du rythme cardiaque au cours de l’anesthesie par l’halothane. Ann. Anesth. franc. 7, 525–530 (1966).Google Scholar
  291. Johnsson, G.: The effect of intra-arterially administered propranolol and H 56/28 on blood flow in the forearm-a-comparative study of two β-adrenergic receptor antagonists. Acta Pharmacol. (Kbh.) 25, Suppl. II, 63–74 (1967).Google Scholar
  292. Johnsson, G., Norby, A., Sölvell, L.: Potency and time effect relationship in man of propranolol and H-56-28.1. Comperative studies after intravenous administration. II. Studies on the ratio of equipotent oral and intravenous doses. Acta pharmacol. (Kbh.) 25, 95–105 (1967).Google Scholar
  293. Johnstone, M.: Die kardiovasculären Wirkungen der Anaesthesie, mit besonderer Berücksichtigung der pharmakologischen Blockade der β-Rezeptoren des Myokards. Anaesthesist 18, 215–217 (1964a).Google Scholar
  294. Johnstone, M.: Propranolol (Inderal) during halothane anaesthesia. Brit. J. Anaesth. 38, 516–529 (1966b).PubMedGoogle Scholar
  295. Johnstone, M.: Beta adrenergic blockade with Inderal (propranolol) during anaesthesia. Anaesthesist 15, 96–99 (1966c).PubMedGoogle Scholar
  296. Johnstone, M.: Beta-adrenergic blockade in anaesthetics. Opusc. med. (Stockh.) 9, 1–6 (1966 d).Google Scholar
  297. Jorfeldt, L., Löfström, B., Möller, J., Rosen, A.: Propranolol in ether anaesthesia. Cardiovascular studies in man. Acta anaesth. scand. 11, 159–169 (1967).PubMedGoogle Scholar
  298. Jose, A. D.: Effect of combined sympathetic and parasympathetic blockade on heart rate and cardiac function in man. Amer. J. Cardiol. 18, 476–478 (1966).PubMedGoogle Scholar
  299. Kabela, E., Mendez, R.: Action of propranolol on the atrioventricular node and on its response to adrenaline and isoprenaline. Brit. J. Pharmacol. 26, 473–481 (1966).PubMedGoogle Scholar
  300. Kahler, R. L., Robinson, B. F., Epstein, S. E., Frommer, P. L., Braunwald, E.: Effects of β-adrenergic blockade on the cardiac response to submaximal exercise studies with a fiberoptic catheter oximeter. Clin. Res. 13, 210 (1965).Google Scholar
  301. Kaltenbach, M., Brunn, V., Becker, H.-J., Graef, V.: Körperliche Leistungsfähigkeit und Muskeldurchblutung beim hyperkinetischen Herzsyndrom. Dtsch. med. Wschr. 94, 1314–1319 (1969).Google Scholar
  302. Kaltenbach, M., Zimmermann, D.: Zur Wirkung von Verapamil auf die Angina pectoris und die adrenergischen β-Rezeptoren des Menschen. Dtsch. med. Wschr. 93, 25–28 (1968).PubMedGoogle Scholar
  303. Karges, O.: Beta-Rezeptorenblocker bei Angina pectoris und Herzrhythmusstörungen. Med. Klin. 64, 1280–1285 (1969).PubMedGoogle Scholar
  304. Kato, H., Hirose, M., Yamaguchi, M., Yqshizawa, Y., Fukuda, H., Oda, T., Nagayama, T.: Hemodynamic effects of isoproterenol and propranolol in tetralogy of Fallot. Production and treatment of anoxic spells. Jap. Circulat. J. (Ni.) 31, 1855–1856 (1967).Google Scholar
  305. Keelan, P.: Double-blind trial of propranolol (Inderal) in angina pectoris. Brit. med. J. 1965 I, 897–898.Google Scholar
  306. Kernohan, R. J.: Propranolol in paroxysmal ventricular tachycardia. Brit. Heart J. 28, 577–578 (1966).PubMedGoogle Scholar
  307. Kernohan, R. J.: Hemodynamic effects of propranolol. Brit. med. J. 1967 II, 177.Google Scholar
  308. Kernohan, R. J., Neely, R. A.: Serum-transaminase levels in patients treated with propranolol. Lancet 1964II, 1338–1339.Google Scholar
  309. Kirchhoff, H. W., Kuemmerle, H. P., Duesterlho, J. V.: Vergleichende Untersuchungen über den Einfluß von β-Rezeptorenblockern auf verschiedene Kreislaufparameter I. und II. Mitteilung. It. Z. klin. Pharmakol. Ther. Toxikol. 2, 229–245 u. 300–314 (1969).Google Scholar
  310. Koch-Weser, J.: Direct and beta adrenergic receptor blocking actions of nethalide on isolated heart muscle. J. Pharmacol, exp. Ther. 146, 318–326 (1964).Google Scholar
  311. Koch-Weser, J.: Effect of propranolol on myocardial actions of ouabain and acetylstrophanthidin. Fed. Proc. 25, 621 (1966).Google Scholar
  312. Koch-Weser, J.: Beta adrenergic blockade and circulating eosinophils. Arch, intern. Med. 121, 255–258 (1968).Google Scholar
  313. Köhler, R., Rtjtishauser, W., Gander, M., Babotai, J.: Changes in the dynamics of the left ventricle of the dog during paired stimulation before and after beta-blockade. Cardiologia (Basel) 49, 135–138 (1966).Google Scholar
  314. Kohli, J. D., Ling, G. M.: Alpha-adrenergic blocking action of propranolol. J. Pharm. Pharmacol. 19, 629–631 (1967).PubMedGoogle Scholar
  315. Kontos, H. A., Lower, R. R.: Role of beta adrenergic receptors in the circulatory response to hypoxia. Circulation 36, Suppl. II, 164 (1967).Google Scholar
  316. Koppelmann, J., Friedebold, G.: Die konservative Behandlung der Claudicatio intermittens durch neurozirkulatorische Regulation. Med. Klin. 63, 382–384 (1968).PubMedGoogle Scholar
  317. Koppelmann, J., Friedebold, G.: Zur Therapie der Claudicatio intermittens. Klinische Untersuchungen zur pharmakologischen Beeinflussung. Med. Klin. 64, 199–202 (1969).PubMedGoogle Scholar
  318. Korol, B., Brown, M. L.: The role of the beta-adrenergic system in behavior: antidepressant effects of propranolol. Curr. ther. Res. 9, 269–279 (1967).PubMedGoogle Scholar
  319. Kotler, M. N., Berman, L., Hubenstein, A. H.: Hypoglycaemia precipitated by propranolol. Lancet 1966II, 1389–1390.Google Scholar
  320. Kraupp, O.: Das pharmakodynamische Wirkungsspektrum der Beta-Rezeptorenblocker. Wien. med. Wschr. 118, 696–699 (1968).PubMedGoogle Scholar
  321. Krayenbühl, H. P., Kako, K., Lüthy, E., Hegglin, R.: Die Systolenlänge und ihre Korrelationen während Volumenänderungen und Druckbelastungen beim Hundeherzen. Cardiologia (Basel) 44, 87–104 (1964).Google Scholar
  322. Krüger, K.: Beitrag zur Pathogenese und medikamentösen Therapie sympathikohyper- toner Herzkreislaufstörungen. Therapiewoche 18, 1413–1419 (1968).Google Scholar
  323. Kuschinsky, G., Rahn, K. H.: Untersuchungen über die Beziehungen zwischen chinidin- artigen und ß-adrenolytischen Wirkungen von l-(3-Methylphenoxy)-2-hydroxy-3-isopropylaminopropan (KÖ 592). Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 252, 50–62 (1965).Google Scholar
  324. Kutscha, W.: Zur Anwendung von Beta-Rezeptoren-Blockern in der Herztherapie. Med. Welt (Stuttg.) 18, 1639 (1967).Google Scholar
  325. Lands, A. M.: Sympathetic receptor action. Amer. J. Physiol. 169, 11–21 (1952).PubMedGoogle Scholar
  326. Langer, J.: The bronchoconstrictor action of propranolol aerosol in asthmatic subjects. J. Physiol. (Lond.) 190, 41 (1967).Google Scholar
  327. Langley, J. N.: On the reaction of cells and of nerve endings to certain poisons chiefly as regards the reaction of striated muscle to nicotine and to curare. J. Physiol. (Lond.) 33, 374–413 (1905).Google Scholar
  328. Larsen, A. A., Lish, P. M.: A new bio-isostere: Alkylsulphonamidophenethanolamines. Nature (Lond.) 203, 1283–1284 (1964).Google Scholar
  329. Laszlö, B., Laszlö, K.: Therapeutic experiences in the clinical use of Inderal (propranolol). Wien. klin. Wschr. 79, 875–878 (1967).PubMedGoogle Scholar
  330. Ledwich, J. R.: A trial of propranolol in myocardial infarction. Canad. med. Ass. J. 98, 988–994 (1968).PubMedGoogle Scholar
  331. Lendle, L., Dalri, H., Schmidt, G.: Zur Verwendung von β-Rezeptorenhemmstoffen bei Atropinvergiftungen. Dtsch. med. Wschr. 91, 1299–1303 (1966).PubMedGoogle Scholar
  332. Levitt, B., Ehereich, S. J., Roberts, J.: Blockade of digitalis-induced ventricular arrhythmia in the cat. Pharmacologist 6, 166 (1964).Google Scholar
  333. Levitt, B., Roberts, J.: Effect of quinidine and pronethalol on acetylstrophanthidin-induced ventricular arrhythmias in cats treated with reserpine. Circulât. Res. 19, 622–631 (1966).PubMedGoogle Scholar
  334. Levy, B., Ahlquist, R. P.: Adrenergic receptors in intestinal smooth muscle. Ann. N. Y. Acad. Sei. 189, 781–787 (1967).Google Scholar
  335. Levy, J. V.: Myocardial and local anaesthetic actions of beta- adrenergic blocking drugs: Relationships to physico-chemical properties. Europ. J. Pharmacol. 2, 250–257 (1968).Google Scholar
  336. Lew, H. T., March, H. W.: Propranolol in cardiac arrhythmias. Clin. Res. 15, 94 (1967).Google Scholar
  337. Lewis, C. M., Brink, A. J., Theron, M. J., Kotze, J. C. N.: Beta-adrenergic blockade. Hemodynamics and myocardial energy metabolism in patients with ischemic heart disease. Amer. J. Cardiol. 21, 846–859 (1968).PubMedGoogle Scholar
  338. Linhart, J. W., Brauetwald, E., Ross, J.: Determinants of the duration of the refractory period of the atrioventricular nodal system in man. J. clin. Invest. 44, 883–890 (1965).PubMedGoogle Scholar
  339. Linko, E., Siitonen, L., Ruosteenoja, R.: A new beta-adrenergic receptor blocking agent (H 56/28), in the treatment of cardiac arrythmias. Acta med. scand. 181, 547–555 (1967).PubMedGoogle Scholar
  340. Lish, P. M., Shelanski, N. V., La Budde, J. A., Williams, W. R.: Inhibition of cardiac chronotropic action of isoproterenol by Sotalol (MJ 1999) in rat, dog and man. Curr. ther. Res. 9, 311–324 (1967).PubMedGoogle Scholar
  341. Lish, P. M., Weikel, J. H., Dungan, K. W.: Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists. J. Pharmacol, exp. Ther. 149, 161–173 (1965).Google Scholar
  342. List, W. F., Marsoker, J. H.: Erfahrungen mit Propranolol während und nach Eingriffen am Herzen. Anaesthesist 3, 82–85 (1968).Google Scholar
  343. Loegering, D. J., Critz, J. B.: The effect of noradrenaline infusions and adrenergic blocking agents on serum glutamic-oxalacetic transaminase in dogs. Canad. J. Physiol. Pharmacol. 46, 627–633 (1968).Google Scholar
  344. Lohmöller, G., Lydtin, H.: Hyperkinetisches Herzsyndrom. Med. Klin. 64, 2015–2019 (1969).Google Scholar
  345. Lord, C. O., Katz, R. L., Eakins, K. E.: Antiarrhythmic properties of stereoisomers of a beta-adrenergic blocking agent (H 56/28) Anesthesiology 29, 288–294 (1968).PubMedGoogle Scholar
  346. Loubatieres, A., Bouyard, P., Klein, M., Caussidier, L.: Actions inotropes cardiaques de l’ouabaine et de divers analeptiques après blocage des recépteurs /5-adrénergiques chez le chien anesthésié. C. R. Soc. Biol. (Paris) 159, 950–953 (1965).Google Scholar
  347. Lubawski, I., Wale, J.: Studies with LB46, a new β-receptor blocking drug. Europ. J. Pharmacol. 6, 345–348 (1969).Google Scholar
  348. Lucchesi, B. R., Whitsitt, L. S.: The pharmacology of beta-adrenergic blocking agents. Prog, cardiovasc. Dis. 11, 410–430 (1969).Google Scholar
  349. Lujf, A., Moser, K.: Beobachtungen über die Wirkung von Inderal auf Hämodynamik und Herzrhythmusstörungen beim Menschen. Wien. klin. Wschr. 79, 343–349 (1967).PubMedGoogle Scholar
  350. Lundholm, L., Svedmyr, N.: Effect of pronethalol on the vasodilatory and lactic acid stimulating effects of adrenaline in the human forearm. Acta pharmacol. (Kbh.) 24, 323–330 (1966).Google Scholar
  351. Luria, M. H., Adelson, E. J., Miller, A. J.: Acute and chronic effects of an adrenergic ß-reeeptor blocking agent (Propranolol) in treatment of cardiac arrhythmias. Circulation 34, 767–773 (1966).PubMedGoogle Scholar
  352. Luria, M. H., Miller, A. G., Kaplan, B. M.: Successful therapy of prolonged hypotension with adren-ergic β-reeeptor blocking agent. Circulation 29, 494–498 (1964).PubMedGoogle Scholar
  353. Lydtin, H.: Die medikamentöse Blockade der adrenergen β-Rezeptoren. Dtsch. med. Wschr. 92, 401–405 (1967).PubMedGoogle Scholar
  354. Lydtin, H.: Beta-Rezeptorenblocker und Anästhesie. Med. Welt. 20, 1889–1894 (1969).Google Scholar
  355. Lydtin, H.: Behandlung mit β-Rezeptorenblockern. Dtsch. med. Wschr. 94, 2560–2562 (1969).PubMedGoogle Scholar
  356. Lydtin, H., Dietze, G.: Klinische Erfahrungen bei der Behandlung der Angina pectoris und des juvenilen Hochdruckes. In D. Haan: Beta-Rezeptorenblockade, Kreisl.-Bücherei, Bd. 23, S. 41–46. Darmstadt: Dr. Dietrich Steinkopff 1967.Google Scholar
  357. Lydtin, H., Kusus, T., Daniel, W., Schierl, W., Ackenheil, M.: Wirkungen und Nebenwirkungen von Propranolol bei Hypertonikern (i. Druck).Google Scholar
  358. Lydtin, H., Kusus, T., Dietze, G., Schnelle, K.: Über die Wirkung eines adrenergen β-Rezeptoren-Blockers auf kardiale Rhythmusstörungen bei experimenteller Bariumvergiftung. Arzneimittel-Forsch. 17, 1456–1459 (1967a).Google Scholar
  359. Lydtin, H., Schnelle, K., Lohmöller, G., Kusijs, T.: Über Diagnose und Therapie des hyperkinetischen Herzsyndroms. Verh. dtsch. Ges. inn. Med. 75, 402–405 (1969).PubMedGoogle Scholar
  360. Lydtin, H., Schnelle, K., Zöllner, N.: Über die Wirkung einer adrenergen ß-Rezeptorenblockade auf die Kontraktilität des gesunden menschlichen Herzens. Z. ges. exp. Med. 143, 67–78 (1967b).Google Scholar
  361. Macalpin, R. M., Kattus, A. A., Winfield, M. E.: The effect of a beta-adrenergic blocking agent (Nethalide) and nitroglycerin on exercise tolerance in angina pectoris. Circulation 31, 869–875 (1965).PubMedGoogle Scholar
  362. Macdonald, A. G., Mc Neill, R. S.: A comparison of the effect on airway resistance of a new beta blocking drug, ICI50,172 and propranolol. Brit. J. Anaesth. 40, 508–510 (1968).Google Scholar
  363. Macdonald, H. R., Sapru, R. P., Taylor, St. H., Donald, K. W.: Effect of intravenous propranolol on the systemic circulatory response to sustained handgrip. Amer. J. Cardiol. 18, 333–344 (1966).PubMedGoogle Scholar
  364. Machtens, E., Opitz, K.: Die Anwendung von beta-Rezeptorenblockern zur Verhütung von Gefahren der Lokalanästhesie. Dtsch. zahnärztl. Z. 22, 374–379 (1967).PubMedGoogle Scholar
  365. Machtens, E., Tetsch, P.: Die injizierbare Kombination eines Lokalanästhetikums mit einem beta- Rezeptorenblocker. Dtsch. zahnärztl. Z. 23, 581–582 (1968).PubMedGoogle Scholar
  366. Mackintosh, T. F.: Propranolol and hypoglycaemia. Lancet 1967 I, 104–105.Google Scholar
  367. Mahon, W. A.: The peripheral vascular effects of beta adrenergic blocking agents in man. Angiologica (Basel) 3, 304–317 (1966).Google Scholar
  368. Mahon, W. A., Reid, D. W. J., Day, R. A.: The in vivo effects of beta-adrenergic stimulation and blockade on the human uterus at term. J. Pharmacol, exp. Ther. 156, 178–185 (1967).Google Scholar
  369. Marcelle, R., Bottin, R., Juchmes, J., Lecomte, J.: Reactions broncho-motrices de Thomme sain apres blocage des recepteurs ß-adrenergiques. Acta allerg. (Kbh.) 23, 11–17 (1968).Google Scholar
  370. March, W., Lew, H. T.: Beta-adrenergic blockade and left ventricular performance in patients with heart disease. J. clin. Invest. 46, 1091 (1967).Google Scholar
  371. Marchetti, G., Merlo, L., Noseda, V.: The activity of some new adrenergic receptor blocking drugs. Arzneimittel-Forsch. 18, 43–48 (1968).Google Scholar
  372. Marmo, E., Coscia, L., Matera, A., Aulisio, G. A.: Beta-adrenolitici e muscolatura trache- ale: Ricerche sperimentali con Pronethalolo, Propranolol, KÖ 592, CIBA 39’089-Ba, H 56/28, MJ 1998, MJ 1999, Methoxamina, Isopropoxamina, Butoxamina, Iproveratril e Ro 3-3528. Arch. ital. Laringol. 75, 249–262 (1967).PubMedGoogle Scholar
  373. Marmo, E., Coscia, L., Matera, A., Aulisio, G. A.: Beta-Adrenolytica, Koronarfluß, Frequenz und Weite der Herzkontraktionen. Cardiologia 52, 177–189 (1968).PubMedGoogle Scholar
  374. Marmo, E., Coscia, L., Matera, A., Aulisio, G. A.: ß-Adrenolytica und Magenmuskulatur. Experimentelle Untersuchungen mit Pronethalol, Propranolol, Kö 592, Ciba 39’089-Ba, H 56/28, MJ 1998, MJ 1999, Methoxamin, Isopropoxamin, Butoxamin, Verapamil und Ro 3-3528. Arzneimittel-Forsch. 18, 1143 bis 1147 (1968).Google Scholar
  375. Marsden, C. D., Gimlette, F. M. D., McAllister, R. G., Owen, D. A. L., Miller, T. N.: Effect of beta-adrenergic blockade on finger tremor and achilles reflex time in anxious and thyrotoxic patients. Acta endocr. (Kbh.) 57, 353–362 (1968).Google Scholar
  376. Marsden, C. D., Owen, D. A. L.: Mechanism unterlying emotional variation in parkinsonian tremor. Neurology (Minneap.)17, 711–715 (1967).Google Scholar
  377. Masuoka, D., Hansson, E.: Autoradiographic distribution studies of adrenergic blocking agents. II. 14 C-propranolol, a beta-receptortype blocker. Acta, pharmacol. (Kbh.) 25, 447–455 (1967).Google Scholar
  378. Mayer, S. E., Williams, B. J., Smith, J. M.: Adrenergic mechanisms in cardiac glycogen metabolism. Ann. N. Y. Acad. Sei. 139, 686–702 (1967).Google Scholar
  379. Mc Culloch, M. W., Proctor, C., Rand, M. J.: Evidence for an adrenergic homeostatic bronchodilator reflex mechanism. Europ. J. Pharmacol. 2, 214–223 (1967).Google Scholar
  380. Mc Devitt, D. G., Shanks, R. G., Hadden, D. R., Montgomery, D. A. D., Weaver, J. A.: The role of the thyroid in the control of heart-rate. Lancet 19681, 998–1000.Google Scholar
  381. Mc Kenna, D. H., Corliss, R. J., Sialer, S., Zarnstorff, W. C., Crumpton, C. W., Rowe, G. G.: Effect of propranolol on systemic and coronary hemodynamics at rest and during simulated exercise. Circulat. Res. 19, 520–527 (1966).Google Scholar
  382. Mc Lean, A. G.: Adrenergic beta-blockade in thyrotoxic crisis. Med. J. Aust. 1, 229 (1967).Google Scholar
  383. Lean, C. E., Stoughton, P. V., Kagey, K. S.: Experiences with beta-adrenergic blockade Vase. Surg. 1, 108–126 (1967).Google Scholar
  384. Mc Neill, R. S.: Effect of a ß-adrenergic-blocking agent, propranolol, on asthmatics. Lancet 1964II, 1101–1102.Google Scholar
  385. Neill, R. S., Ingram, C. G.: Effect of propranolol on ventilatory function. Amer. J. Cardiol. 18, 473–475 (1966).Google Scholar
  386. Meesmann, W.: Klinische Erfahrungen bei der Behandlung der Angina pectoris, der Tachykardien und der hypertonen Regulationsstörungen mit Propranolol (Dociton). Beta- Eezeptorenblockade, S. 67–70. Darmstadt: Dr. Dietrich Steinkopff 1967.Google Scholar
  387. Meier, J.: Über die Wirkung eines neuen β-Rezeptorenblockers (ICI50172) auf Kreislaufund Bronchialsystem. Verh. dtsch. Ges. inn. Med. 75, 399–402 (1969).PubMedGoogle Scholar
  388. Meier, J., Lydtin, H., Zöllner, N.: Über die Wirkung von adrenergen β-Rezeptorenblockern auf ventilatorische Funktionen bei obstruktiven Lungenkrankheiten. Dtsch. med. Wschr. 91, 145–147 (1966).PubMedGoogle Scholar
  389. Meier, M., Hedwall, P. R., Brunner, H.: Beeinflussung der Wirkung von Hydralazin durch adrenergische Beta-Blockade. Arch. exp. Path. Pharmakol. 251, 131–132 (1965).Google Scholar
  390. Melville, K. J., Benfey, B. G.: Coronary vasodilatory and cardiac adrenergic blocking effects of iproveratril. Canad. J. Physiol. Pharm. 43, 339–342 (1965).PubMedGoogle Scholar
  391. Miller, J. W.: Adrenergic receptors in the myometrium. Ann. N. Y. Acad. Sei. 139, 788–798 (1967).Google Scholar
  392. Moissejew, S., Ustinowa, E.: Anwendung von adrenergen Beta-Rezeptoren-Blockern bei Herzrhythmusstörungen. Int. Z. klin. Pharmakol. Ther. Toxikol. 5, 406–407 (1968).Google Scholar
  393. Molzahn, M., Dissmann, Th., Götzen, R.: Kreislaufveränderungen nach akuter Anwendung von Propranolol bei beginnender und fortgeschrittener essentieller Hypertonie. Verh. dtsch. Ges. inn. Med. 74, 570–574 (1968).PubMedGoogle Scholar
  394. Morales-Aguilera, A., Vaughan Williams, E. M.: The effects on cardiac muscle of ß-rezeptor antagonists in relations to their activity as local anaesthetics. Brit. J. Pharmacol. 24, 332–338 (1965).PubMedGoogle Scholar
  395. Moran, N. C.: Pharmacological characterization of adrenergic receptors. Pharmacol. Rev. 18, 503–512 (1966).PubMedGoogle Scholar
  396. Moran, N. C.: The development of beta adrenergic blocking drugs: a retrospective and prospective evaluation. Ann. N. Y. Acad. Sei. 139, 649–660 (1967).Google Scholar
  397. Moran, N. C.: Perkins, E.: Adrenergic blockade of the mammalian heart by a dichloroanalogue of isoproterenol. J. Pharmacol, exp. Therap. 124, 223–237 (1958).Google Scholar
  398. Moser, K., Ltjjf, A.: Doppelblindversuche mit Inderal bei Angina pectoris. Wien. Klin. Wschr. 79, 349–352 (1967).PubMedGoogle Scholar
  399. Müller, C., Dietzel, W., Schmitz, W., Wolter, H.: Die Anwendung der Rezeptoren-Blockade bei operativen Eingriffen am Herzen. Anaesthesist 16, 97–100 (1967).Google Scholar
  400. Nakano, J., Kusakari, F.: Effect of propranolol on the peripheral vascular bed. Nature (Lond.) 209, 923–924 (1966).Google Scholar
  401. Nakano, J., Kusakari, F., Berry, J. L.: Effects of propranolol on the circulatory changes and mobilization of free fatty acids caused by isoproterenol. Arch. int. Pharmacodyn. 164, 120–127 (1966).PubMedGoogle Scholar
  402. Nash, C. B.: Dual adrenergic blockade and epinephrine infusion. J. Pharmacol, exp. Ther. 162, 246–253 (1968).Google Scholar
  403. Natu, M. V., Deepak Bose, Gandhi, J. S., Seth, C. B.: Anticonvulsant action of some beta-adrenergic receptor blocking agents. Curr. Sei. 37, 529 (1968).Google Scholar
  404. Nayler, W. G., Mc Innes, I., Carson, V., Wann, J. S., Lowe, T. E.: The combined effect of atropine and β-adrenergic receptor antagonists on left ventricular function and coronary blood flow. Amer. Heart. J. 77, 246–258 (1969).PubMedGoogle Scholar
  405. Nestel, P. J.: Evaluation of propranolol (Inderal) in the treatment of angina pectoris. Med. J. Aust. 2, 1274–1276 (1966).PubMedGoogle Scholar
  406. Nielsen, B. L., Schönau-Jorgensen, F.: Propranolol (Inderal) in cardiac arrhythmias. Acta med. scand. 180, 631–638 (1966).PubMedGoogle Scholar
  407. Nordenfelt, O.: Orthostatic E. C. G. changes and the adrenergic beta-receptor blocking agent, propranolol (Inderal). Acta med. scand. 178, 393–401 (1965).PubMedGoogle Scholar
  408. Norris, H. M., Caughey, D. E., Scott, P. J.: Trial of propranolol in acute myocardial infarction. Brit. med. J. 1968 II, 398–400.Google Scholar
  409. Opitz, K., Chu, H.: Zur stoffwechselsteigernden Wirkung der Brenzkatechinamine. Naunyn- Schmiedebergs Arch. Pharmak. exp. Path. 259, 329–343 (1968).Google Scholar
  410. Ouellette, J. J., Reed, Ch. E.: The effect of partial beta adrenergic blockade on the bron-chial response of hay fever subjects to ragweed aerosol. J. Allergy 39, 160–166 (1967).PubMedGoogle Scholar
  411. Owen, D. A. L., Marsden, C. D.: Effect of adrenergic beta-blockade on parkinsonian tremor: Lancet 1965 II, 1259–1262.Google Scholar
  412. Papp, J., Förster, W., Szekeres, L., Rösler, V.: Action of beta-receptor blocking sym-patholytics and of catecholamine depleting agents on CaCl2-induced arrhythmias in rats. Experientia (Basel) 22, 524–525 (1966).Google Scholar
  413. Parker, J. O., West, R. O., Di Giorgi, S.: Hemodynamic effects of propranolol in coronary heart disease Amer. J. Cardiol. 21, 11–19 (1968).Google Scholar
  414. Parratt, J. R., Grayson, J.: Myocardial vascular reactivity after beta-adrenergic blockade. Lancet 19661, 338–340.Google Scholar
  415. Parratt, J. R., Grayson, J.: Wads worth, R. H.: Myocardial and haemodynamic effects of the beta-adrenoceptor blocking drug alprenolol (H 56/28) in anaesthetized cats. Brit. J. Pharmacol. 37, 357–366 (1969).Google Scholar
  416. Parsons, V., Jewitt, D.: Beta-adrenergic blockade in the management of acute thyrotoxic crisis, tachycardia and arrythmias. Postgrad, med. J. 43, 756–762 (1967).Google Scholar
  417. Pastelin, G., de Micheli, A., Valadez, F., Mendez, R.: Efectos antagonicos y aditivos del propranolol con los digitalicos. Arch. Inst. Cardiol. Mex. 37, 221–235 (1967).PubMedGoogle Scholar
  418. Paterson, J. W., Dollery, C. T.: Effect of propranolol in mild hypertension. Lancet 1966 II, 1148–1150.Google Scholar
  419. Paton, D. M.: Beta-receptor blockade in the diagnosis of phaeochromocytoma. Lancet 1964 II, 1125.Google Scholar
  420. Paton, W. D. M.: Adrenergic receptors in the light of general receptor theories. Ann. N.Y. Acad. Sei. 189, 632–644 (1967).Google Scholar
  421. Payne. J. P., Senfield, R. M.: Pronethalol in treatment of ventricular arrhythmias during anaesthesia. Brit. med. J. 19641, 603–604.Google Scholar
  422. Pentecost, B. L., Austen, W. G.: Beta-adrenergic blockade in experimental myocardial infarction. Amer. Heart. J. 71, 790–796 (1966).Google Scholar
  423. Pharmley, W. W., Braunwald, E.: Comparative myocardial depressant and anti-arrhythmic properties of d-propranolol, dl-propranolol and quinidine. J. Pharmacol, exp. Ther. 158, 11–21 (1967).Google Scholar
  424. Phillips, C. J., Howitt, G., Rowlands, D. J.: Propranolol as ocular hypotensive agent. Brit. J. Ophthal. 51, 222–226 (1967).PubMedGoogle Scholar
  425. Pilkington, T. R. E., Lowe, R. D., Foster, R., Robinson, B. F., Antonis, A.: Effect of sympathomimetic compounds with beta-adrenergic effects on plasma free fatty acids in man. J. Lipid Res. 7, 73–76 (1966).PubMedGoogle Scholar
  426. Pinter, E. J., Pattee, C. J.: Effect of beta-adrenergic blockade on resting and stimulated fat mobilization. J. clin. Endocr. 27, 1441–1450 (1967).PubMedGoogle Scholar
  427. Pinter, E. J., Peterfy, G., Cleghorn, J. M., Pattee, C. J.: The influence of emotional stress on fat mobilization. The role of endogenous catecholamines and the β-adrenergic receptors. Amer. J. med. Sei. 254, 634–650 (1967).Google Scholar
  428. Pippig, L.: Die Wirkung eines adrenergischen ß-Rezeptoren-Blockers (Nethalide) auf die Ruhehämodynamik des Menschen. Med. Klin. 60, 1769–1773 (1965).PubMedGoogle Scholar
  429. Pitt, B., Elliot, E. C., Gregg, D. E.: Adrenergic receptor activity in the coronary arteries of the unanaesthetized dog. Circulat. Res. 21, 75–84 (1967).PubMedGoogle Scholar
  430. Pitt, W. A., Cox, A. R.: The effect of the β-adrenergic antagonist propranolol on rabbit atrial cells with the use of the ultramicroelectrode technique. Amer. Heart J. 76, 242–248 (1968).PubMedGoogle Scholar
  431. Pitts, F. N., Jr., Mc Clure, J. N., Jr.: Lactate metabolism in anxiety neurosis. New Engl. J. Med. 277, 1329–1336 (1967).PubMedGoogle Scholar
  432. Pöntinen, P. J., Ekholm, K., Levänen, J., Toivio, I.: Further experiences with beta- receptor-blockade in the treatment of cardiac arrhythmias during anaesthesia. Duodecim (Helsinki) 81, 1331–1337 (1965).Google Scholar
  433. Porte, D., Jr.: A receptor mechanism for the inhibition of insulin release by epinephrine in man. J. clin. Invest. 46, 86–94 (1967a).PubMedGoogle Scholar
  434. Porte, D., Jr.: Beta adrenergic stimulation of insulin release in man. Diabetes 16, 150–155 (1967b).PubMedGoogle Scholar
  435. Powell, C. E., Slater, I. H.: Blocking of inhibitory adrenergic receptors by a dichloro-analogue of isoproterenol. J. Pharmacol, exp. Ther. 122, 480–488 (1958).Google Scholar
  436. Price, H. L., Cooperman, L. H., Warden, J. C.: Control of the splanchnic circulation in man. Role of beta-adrenergic receptors. Circulât. Res. 21, 333–340 (1967).PubMedGoogle Scholar
  437. Prichard, B. N. C., Gillam, P. M. S.: Treatment of hypertension with propranolol. Brit, med. J. 19691, 7–15.Google Scholar
  438. Prichard, B. N. C., Ross, E. J.: Use of propranolol with alpha receptor blocking drugs in pheochromocytoma. Amer. J. Cardiol. 18, 394–398 (1966).PubMedGoogle Scholar
  439. Rabkin, R., Stables, D. P., Levin, N. W., Suzman, M. M.: The prophylactic value of propranolol in angina pectoris. Amer. J. Cardiol. 18, 370–383 (1966).PubMedGoogle Scholar
  440. Rahn, K. H., Retjter, H.: Die Wirkung von β-Rezeptoren blockierenden Substanzen auf die durch Adrenalin gesteigerte if-Abgabe des Meerschweinchenvorhofes. Naunyn- Schmiedebergs Arch. exp. Path. Pharmak. 253, 484–494 (1966).Google Scholar
  441. Reale, A., Imhof, P., Motolese, M.: Influence of beta-adrenergic blockade on immediate haemodynamic effects of angiocardiography. Brit. Heart J. 29, 761–766 (1967).PubMedGoogle Scholar
  442. Reutter, F. W.: Die Behandlung Digitalis-induzierter Herzrhythmusstörungen mit dem sympathischen Beta-Rzeptorenblocker Propranolol. Cardiologia 50, 251–255 (1967).PubMedGoogle Scholar
  443. Reveno, W. S., Rosenbaum, H.: Propranolol and hypoglycemia. Lancet 19681, 920.Google Scholar
  444. Reynolds, E. W. Jr., Vanderark, C. R.: Treatment of quinidine-resistant arrhythmias with the combined use of quinidine and propranolol. Circulation 36, Suppl. II, 221 (1967).Google Scholar
  445. Richards, F. A.: Propranolol in hypertension.Amer. J. Cardiol. 18, 384–386 (1966).Google Scholar
  446. Richardson, D. W., Freund, J., Gear, A. S., Mauck, H. P., Jr., Preston, L. W.: Effect of propranolol on elavated arterial blood pressure. Circulation 37, 534–542 (1968).PubMedGoogle Scholar
  447. Risio, C. De, Murmann, W.: Anxiety and the pulse. Brit. med. J. 1967 II, 373.Google Scholar
  448. Robertson, A. I. G.: Pre- and post-operative care of patients with phaeochromocytomas. Postgrad, med. J. 41, 481–484 (1965).Google Scholar
  449. Robillard, M., Klotz, B., Perrault, M.: L’inhibition des récepteurs béta-adrénergiques dans le traitement de la maladie de basedow. Presse med. 75, 897–900 (1967).PubMedGoogle Scholar
  450. Robin, E., Cowan, C., Puri, P., Ganguly, S., Boyrie, E. De, Martinez, M., Stock, T., Bing, R. J.: A comparative study of nitroglycerine and propranolol. Circulation 36, 175–186 (1967).PubMedGoogle Scholar
  451. Robison, G. A., Butcher, R. W., Sutherland, E. W.: Adenyl cyclase as an adrenergic receptor. Ann. N.Y. Acad. Sei. 139, 703–723 (1967).Google Scholar
  452. Ronsin, J. C., Dittmar, A., Thomas, G., Chatonnet, J.: A propos du mécanisme de l’action calorigène des catécholamines au niveau du muscle squelettique. C. R. Soc. Biol. (Paris) 161, 821–824 (1967).Google Scholar
  453. Rosen, A., Michaeli, E.: Depression of isoproterenol-induced idioventricular rhythm by beta adrenergic receptor blocking drugs in man. Circulation 36, Suppl. II, 225–226 (1967).Google Scholar
  454. Rosenblum, R., Berkowitz, W. D., Lawson, D.: Effect of acute intravenous administration of isoproterenol on cardiorenal hemodynamics in man. Circulation 38, 158–168 (1968).PubMedGoogle Scholar
  455. Rosenblum, R., Frieden, J., Delman, A. J., Berkowitz, W. D.: Long-term propranolol therapy in patients with idiopathic hypertrophic subaortic stenosis. Circulation 36, Suppl. II, 226 (1967).Google Scholar
  456. Ross, E. J., Prichard, B. N. C., Kaufmann, L., Robertson, A. I. G., Harries, B. J.: Preoperative and operative management of patients with phaeochromocytoma. Brit. med. J. 1967 I, 191–198.Google Scholar
  457. Ross, E. M., Robertson, P. G. C., Watson, H.: Failure of oral propranolol to maintain relief from paroxysmal syncopal attacks in Fallots tetralogy after its sucessful intravenous use. Lancet 1966 II, 945–946.Google Scholar
  458. Ross, G., White, F. N.: Role of catecholamine release in cardiovascular responses to angiotensin. Amer. J. Physiol. 211, 1419–1423 (1966).PubMedGoogle Scholar
  459. Rossignol, P., Keuky, L., Valette, G.: Méchanisme des variations de la réactivité de l’utérus de cobaye aux effects a et ß adrenergiques en fonction du cycle œstral. Arch. int. Pharma- codyn. 158, 324–338 (1965).PubMedGoogle Scholar
  460. Rothfeld, E. L., Lipowitz, M., Zucker, J. R.,Parsonnet, V., Bernstein, A.: Management of persistently recurring ventricular fibrillation with propranolol hydrochloride. J. Amer. med. Ass. 204, 546–548 (1968).Google Scholar
  461. Rouse, W.: Effects of propranolol and ouabain on the conducting system of the heart in dogs. Amer. J. Cardiol. 18, 406–413 (1966).PubMedGoogle Scholar
  462. Rowlands, D. J., Howitt, G., Markman, P.: Propranolol (Inderal) in disturbances of cardiac rhythm. Brit. med. J. 19651, 891–894.Google Scholar
  463. Rudolph, W., Meister, W., Kriener, J.: Untersuchungen über die Substratversorgung und die Koronardurchblutung des menschlichen Herzens unter dem Einfluß von Beta-Rezeptorenblockern. In: Beta-Rezeptorenblockade in Klinik und Experiment. S. 121–131. Wien: Brüder Hollinek 1968.Google Scholar
  464. Russek, H. I.: Propranolol and isosorbide dinitrate synergism in angina pectoris. Amer. J. med. Sei. 254, 406–415 (1967).Google Scholar
  465. Saameli, K.: Vergleichende Untersuchungen mit β-Rezeptorenblockern und Chinidin. Helv. Physiol. Pharmacol. Acta 25, R 432–433 (1967).Google Scholar
  466. Sack, H., Neuhaus, J., Schega, W., Körner, M.: Die Bedeutung der medikamentösen Blockade adrenerger alpha- und beta-Rezeptoren für die konservative und operative Behandlung des Phaechromozytoms. Dtsch. med. Wschr. 93, 151–163 (1968).PubMedGoogle Scholar
  467. Sailer, S., Sandhofer, F., Bolzano, K., Dienstl, F., Braunsteiner, H.: Über die Wirkung eines ß-Blockers (Propranolol) auf den Umsatz der freien Fettsäuren und den Einbau von freien Fettsäuren in Plasmatriglyceride beim Menschen. Klin. Wschr. 45, 670–674 (1967).PubMedGoogle Scholar
  468. Salvador, R. A., April, S. A., Lemberger, L.: Inhibition by butoxamine, propranolol and MJ 1999 of the glycogenolytic action of the catecholamines in the rat. Biochem. Pharmacol. 16, 2037–2041 (1967).PubMedGoogle Scholar
  469. Sandhofer, F., Sailer, S., Bolzano, K., Braunsteiner, H.: Über die Wirkung eines beta- Rezeptorenblockers (Propranolol) auf die Umsatzrate der freien Fettsäuren und deren Einbaurate in Plasmatriglyceride bei Hyperthyreose. Schweiz, med. Wschr. 97, 1319–1323 (1967).Google Scholar
  470. Saner, R. P.: Die Behandlung der Angina pectoris mit einem neuen ß-Rezeptoren-Blocker, dem Präparat LB 46 (4-[2-Hydroxy-3-isopropylaminopropoxy]-indol). Schweiz, med. Wschr. 100, 174–179 (1970).Google Scholar
  471. Scales, B., McIntosh, D. A. D.: Effects of propranolol and its optical isomers on the radio- calcium uptake and the adenosine triphosphatases of skeletal and cardiac sarcoplasmic reticulum fractions (SRF). J. Pharmacol, exp. Ther. 160, 261–267 (1968).Google Scholar
  472. Schamroth, L.: Immediate effects of intravenous propranolol on various cardiac arrhythmias. Amer. J. Cardiol. 18, 438–443 (1966).PubMedGoogle Scholar
  473. Schaumann, W., Bodem, R., Bartsch, W.: Kardiale Wirkungen von Prenylamin und Ipro- veratril im Vergleich zu Propranolol, Pronethalol und Ajmalin. Naunyn-Schmiedebergs Arch. Pharmak. exp. Path. 255, 328–343 (1966).Google Scholar
  474. Scheu, H., Bollinger, A., Wirz, P.: Medizinische Behandlung der idiopathischen hypertrophischen Subaortenstenose. Schweiz, med. Wschr. 95, 1652–1654 (1965).Google Scholar
  475. Schilli, W., Büchner, Ch., Gebhardt, W.: Das Kreislauf verhalten unter Lokalanaesthesie mit Epinephrinzusatz nach Blockade der beta-Rezeptoren. Dtsch. zahnärztl. Z. 21, 1255–1258 (1966).PubMedGoogle Scholar
  476. Schirmeister, J., Decot, M., Hallauer, W., Willmann, H.: β-Rezeptoren und renale Hämodynamik des Menschen. Arzneimittel-Forsch. 16, 847–850 (1966).Google Scholar
  477. Schmid, J. R., Hanna, C.: A comparison of the antiarrhythmic actions of two new synthetic compounds, iproveratril and MJ 1999, with quinidine and pronethalol. J. Pharmacol, exp. Ther. 156, 331–338 (1966).Google Scholar
  478. Schmidt, H. D., Schmier, J.: Das Verhältnis von kardiodepressiver zu adrenolytischer Wirkung bei verschiedenen β-Rezeptorenblockern am Herz-Lungen-Präparat des Hundes. Klin. Wschr. 45, 688–697 (1967).PubMedGoogle Scholar
  479. Schmidt-Voigt, J., Pecher, H.: Langzeitbehandlung mit einem ß-Rezeptoren-Blocker. Fortschr. Med. 87, 1041–1042 (1969).Google Scholar
  480. Schnelle, K.: Persönliche Mitteilung.Google Scholar
  481. Schröder, G., Werkö, L.: Haemodynamic studies and clinical experience with nethalide, a beta-adrenergic blocking agent. Amer. J. Cardiol. 15, 58–65 (1965).Google Scholar
  482. Schwandt, P., Hartmann, Th., Karl, H. J.: Der Einfluß von Nicotinsäure und Propranolol auf die lipolytische Wirkung von Catecholaminen und Peptidhormonen in vitro. Z. ges. exp. Med. 143, 79–84 (1967).Google Scholar
  483. Schweitzer, P., Hildebrand, T., Klvanová, H., Simko, S., Galajdová, E., Gregorova, J.: Der Einfluß der adrenergen Blockade auf die orthostatischen Veränderungen der Integralvektoren von QRS, T sowie des Ventrikelgradienten bei Patienten mit neurozirkulatorischer Asthenie und Thyreotoxikose. Z. Kreisl.-Forsch. 56, 316–325 (1967).Google Scholar
  484. Seaton, A.: Quinidine-induced paroxysmal ventricular fibrillation treated with propranolol. Brit. med. J. 1966 II, 1522.Google Scholar
  485. Segel, N., Bishop, J. M.: The circulatory effects of pronethalol with special reference to changes in heart rate and stroke volume during exercise. Clin. Sei. 29, 363–373 (1965).Google Scholar
  486. Shah, P. M., Amarasingham, R., Oakley, C. M.: Haemodynamic effects of changes in blood volume in hypertrophic obstructive cardiomyopathy. Brit. Heart J. 27, 83–89 (1965).PubMedGoogle Scholar
  487. Shah, P. M., Langford, K.: Circulatory effects of propranolol in children with Fallot’s tetralogy. Observations with isoproterenol infusion, exercise and crying. Amer. J. Cardiol. 19, 653–657 (1967).PubMedGoogle Scholar
  488. Shanks, R. G.: The effect of propranolol on the cardio-vascular response to isoprenaline, adrenaline and noradrenaline in the anaesthetized dog. Brit. J. Pharmacol. 26, 322–333 (1966).PubMedGoogle Scholar
  489. Shanks, R. G.: Propranolol in myocardial infarction. Lancet 1967 I, 788.Google Scholar
  490. Shanks, R. G.: The peripheral vascular effects of propranolol and related compounds. Brit. J. Pharmacol. Chemother. 29, 204–217 (1967).Google Scholar
  491. Shanks, R. G., Ditnlop, D.: Effect of propranolol on arrhythmias following coronary artery occlusion in dogs. Cardiovasc. Res. 1967 I, 34–41.Google Scholar
  492. Shanks, R. G., Hadden, D. R., Lowe, D. C., McDevitt, D. G., Montgomery, D. A. D.: Controlled trial of propranolol in thyrotoxicosis. Lancet 1969 II, 993–994.Google Scholar
  493. Shanks, R. G., Wood, T. M., Dornhorst, A. C., Clark, M. C.: Some pharmacological properties of a new adrenergic beta-receptor antagonist. Nature (Lond.) 212, 88–90 (1966).Google Scholar
  494. Sharma, P. L.: Effect of propranolol on arterial hypotension induced by halothane in the dog unter nitrous oxide anaesthesia. Brit. J. Anaesth. 39, 215–219 (1967).PubMedGoogle Scholar
  495. Shen, Y., Quiroz, A. C., Burch, G. E., Pasquale, N. P. De: Hemodynamic responses to beta-adrenergic blockade in dogs. Amer. Heart J. 73, 669–673 (1967).PubMedGoogle Scholar
  496. Shinebourne, E., Fleming, J., Hamer, J.: Effects of beta-adrenergic blockade during exercise in hypertensive and ischaemic heart disease. Lancet 1967 II, 1217–1220.Google Scholar
  497. Simpson, T.: Propranolol and hypoglycemia. Lancet 19671, 508.Google Scholar
  498. Singh, S. P., Gotsman, M. S.: Pronethalol for cyanotic attacks. Brit. Heart. J. 28, 98–100 (1966).PubMedGoogle Scholar
  499. Sinha, J. N., Jaju, B. P., Misra, U. C., Tewari, J. N., Srimal, R. C.: Clinical efficacy of propranolol as a local anaesthetic. Brit. J. Anaesth. 39, 887–890 (1967 a).Google Scholar
  500. Sinha, J. N., Srimal, R. C., Jaju, B. P., Bhargava, K. P.: On the central muscle relaxant acivity of D.C.I., nethalide and propranolol. Arch. int. Pharmacodyn. 165, 160–166 (1967b).Google Scholar
  501. Sloman, G.: Propranolol in management of muscular subaortic stenosis. Brit. Heart. J. 29, 783–787 (1967).PubMedGoogle Scholar
  502. Sloman, G.: Stannard, M.: Beta adrenergic blockade and cardiac arrhythmias. Brit. med. J. 1967 II, 508–512.Google Scholar
  503. Sly, R. M., Heimlich, E. M., Busser, R. J., Strick, L.: Exercise induced bronchospasm: effect of adrenergic or cholinergic blockade. J. Allergy 40, 93–99 (1967).PubMedGoogle Scholar
  504. Smulyan, H., Eich, R. H.: Effect of beta sympathetic blockade on the initial hemodynamic response to exercise. J. Lab. clin. Med. 71, 378–389 (1968).PubMedGoogle Scholar
  505. Snow, P. J.: Effect of propranolol in myocardial infarction. Lancet 1965 II, 551–553.Google Scholar
  506. Snow, P. J.: Treatment of acute myocardial infarction with propranolol. Amer. J. Cardiol. 18, 458 to 462 (1966).Google Scholar
  507. Somani, P., Bachand, R. T., Jr.: Blockade of cardiac effects of isoproterenol by the stereo-isomers of Sotalol. Europ. J. Pharmacol. 7, 239–247 (1969).Google Scholar
  508. Somani, P., Lum, B. K. B.: The antiarrhytmic actions of beta adrenergic blocking agents. J. Pharmacol, exp. Therap. 147, 194–203 (1965).Google Scholar
  509. Sonnenblick, E. H.: Determinants of 02-consumption of the heart. Herzinsuffizienz, S. 271 to 277. Stuttgart: Thieme 1968.Google Scholar
  510. Sonnenblick, E. H., Braunwald, E., Williams, J. F., Glick, G.: Effects of exersise on myocardial force-velocity relations in intact unanesthetized man: relative roles of changes in heart rate, sympathetic activity and ventricular dimensions. J. clin. Invest. 44, 2051–2062 (1965).PubMedGoogle Scholar
  511. Soulié, P., Forman, J., Delzant, J. F., Sterba, A., Varin, G., Grimberg, D.: Étude des effets hémodynamiques du propranolol dans les sténoses musculaires du ventricule gauche. Coeur. Med. inter. 5, 231–240 (1966).Google Scholar
  512. Sowton, E., Balcon, R., Cross, D., Frick, H.: Haemodynamic effects of ICI 50172 in patients with ischaemic heart disease. Brit. med. J. 1968 I, 215–216.Google Scholar
  513. Sowton, E., Balcon, R., Preston, T., Leaver, D., Yacoub, M.: Long-term control of intractable supraventricular tachycardia by ventricular pacing. Brit. Heart J. 31, 700–706 (1969).PubMedGoogle Scholar
  514. Srivastava, S. C., Dewar, H. A., Newell, D. J.: Double-blind trial of Propranolol (Inderal) in angina of effort. Brit med. J. 1964 II, 724–725.Google Scholar
  515. Standaert, F. G., Roberts, J.: A neural action of pronethalol. Ann. N.Y. Acad. Sci. 139, 815–820 (1967).PubMedGoogle Scholar
  516. Standard, M., Sloman, G., Sangster, L.: The haemodynamic effects of atropine combined with propranolol in acute myocardial infarction. Med. J. Aust. 1, 333–334 (1968).Google Scholar
  517. Stanton, H. C., Kirchgessner, T., Parmenter, K.: Cardiovascular pharmacology of two new beta-adrenergic receptor antagonists. J. Pharmacol, exp. Ther. 149, 174–182 (1965).Google Scholar
  518. Starcich, R., Barbaresi, F., Volta, G., Pavarani, A.: Influenze positive e negative del blocco beta-adrenergico nell’ angina pectoris. Minerva cardioangiol. 15, 835–843 (1967).PubMedGoogle Scholar
  519. Stephen, S. A.: Unwanted effects of propranolol. Amer. J. Cardiol. 18, 463–472 (1966a).PubMedGoogle Scholar
  520. Stephen, S. A.: Propranolol in acute myocardial infarction–a multicentre trial. Lancet 1966 lib, 1435 to 1437.Google Scholar
  521. Sterkowicz, S.: Test inderalowy. Wykorzystanie blockady beta-adrenergicznej w rozpoz- nawaniu rôznicowym nieswoistych zmian zalamka T krzywej ekg. Pol. tyg. Lek. 22,1561 to 1564 (1967).Google Scholar
  522. Stern, S.: Conversion of chronic atrial fibrillation to sinus rhythm with combined propranolol and quinidine treatment. Amer. Heart. J. 74, 170–172 (1967).PubMedGoogle Scholar
  523. Stjarne, L., Lishajko, F.: Drug- induced inhibition of noradrenaline synthesis in vitro in bovine splenic nerve tissue. Brit. J. Pharmacol. 27, 398–404 (1966).PubMedGoogle Scholar
  524. Stock, J. P.: Beta adrenergic blocking drugs in the clinical management of cardiac arrhythmias. Amer. J. Cardiol. 18, 444–449 (1966).PubMedGoogle Scholar
  525. Stock, K., Westermann, E.: Competitive and non-competitive inhibition of lipolysis by α- and β-adrenergic blocking agents, methoxamine derivates, and prostaglandin E. Life Sci. 5, 1667–1678 (1966).Google Scholar
  526. Strässle, B., Burckhardt, D., Mofpert, J.: Therapieversuche an einem Fall von idiopathischer Positionshypotonie. Cardiologia (Basel) 48, 422–424 (1966).Google Scholar
  527. Strang, R. R.: Clinical trial with a beta-receptor antagonist (Propranolol) in parkinsonism. J. Neurol. Neurosurg. Psychiat. 28, 404–406 (1965).PubMedGoogle Scholar
  528. Svedmyr, N.: Blockade of the calorigenic, hyperglycemic, lactic acid-producing and fatty acid-mobilizing effects of adrenaline by an adrenergic beta-receptor blocking agent (pronethalol) in experiments on the rabbit. Acta physiol. scand. 71, 1–5 (1967).PubMedGoogle Scholar
  529. Svedmyr, N., Lundholm, L.: The influence of an adrenergic beta-receptor blocking agent (MJ 1999) on one of the metabolic effects of adrenaline in man. Life Sci. 6, 21 (1967).Google Scholar
  530. Szekeres, L., Papp, J., Fôrster, W.: The action of adrenergic beta-receptor blocking agents on susceptibility to cardiac arrhythmias in hypothermia and hypoxia. Experientia (Basel) 21, 720–722 (1965).Google Scholar
  531. Tanz, R. D.: The action of Ouabain on cardiac muscle treated with reserpine and dichloro- isoproterenol. J. Pharmacol, exp. Ther. 144, 205–213 (1964).Google Scholar
  532. Taylor, J. A.: Hypotension after oral propranolol. Lancet 1968 I, 532–533.Google Scholar
  533. Taylor, R. R., Johnston, C. I., Jose, A. J.: Reversal of digitalis intoxication by beta- adrenergic blockade with pronethalol. New Engl. J. Med. 271, 877–882 (1964).PubMedGoogle Scholar
  534. Tewari, S. N.: Propranolol in hypertension. Brit. med. J. 1968 III, 313–314.Google Scholar
  535. Thompson, R. H., Letley, E.: What is a beta-blocker? Lancet 1967 II, 1149.Google Scholar
  536. Török, E., Matos, L., Rausch, J., Simonyi, J.: The effects of propranolol in essential cir-culatory hyperkinesis. Int. Z. klin. Pharmakol. Ther. Toxikol. 2, 246–252 (1969).PubMedGoogle Scholar
  537. Tourniaire, A., Tartulier, M., Blum, J., Deyrieux, F.: Névrose tachycardique sévère traitée par le propranolol. Étude fonctionnelle respiratoire et hémodynamique cardiaque. Presse méd. 76, 385–386 (1968).PubMedGoogle Scholar
  538. Tschirdewahn, B., Knorpp, K., Heinrich, F., Schütterle, G.: Lebensbedrohliche Herz-rhythmusstörungen und ß-Rezeptoren-Blocker. Dtsch. med. Wschr. 92, 2204–2208 (1967).PubMedGoogle Scholar
  539. Tsolakas, T. C., Davies, J. P. H., Oram, S.: Effect of a beta-adrenergic-blocking agent on the pulmonary circulation in mitral stenosis. Lancet 1965 II, 416–417.Google Scholar
  540. Turner, P., Granville-Grossman, K. L., Smart, J. V.: Effect of adrenergic receptor blockade on the tachycardia of thyrotoxicosis and anxiety state. Lancet 1965 II, 1316–1318.Google Scholar
  541. Ulrych, M., Fröhlich, E. D., Dustan, H. P., Page, I. H.: Immediate hemodynamic effects of beta-adrenergic blockade with propranolol in normotensive and hypertensive man. Circulation 37, 411–416 (1968).PubMedGoogle Scholar
  542. Usubiaga, J. E.: Neuromuscular effects of beta-adrenergic blockers and their interaction with skeletal muscle relaxants. Anesthesiology 29, 484–492 (1968).PubMedGoogle Scholar
  543. Valero, A.: Treatment of severe physostigmine poisoning. Lancet 1968II, 459–460.Google Scholar
  544. Valero, A., Golan, D.: Accidental organic phosphorus poisoning: the use of propranolol to counteract vagolytic cardiac effects of atropine. Israel J. med. Sei. 3, 582–584 (1967).Google Scholar
  545. Varkonyi, G.: Klinische Erfahrungen mit Propranolol bei angina pectoris und bei Rhythmusstörungen des Herzens. Therapiewoche 16, 1334–1337 (1966).Google Scholar
  546. Vas, C. G.: Propranolol in parkinsonian tremor. Lancet 1966 I, 182–183.Google Scholar
  547. Vaughan Williams, E. M.: Mode of action of beta-receptor antagonists on cardiac muscle. Amer. J. Cardiol. 18, 399–405 (1966).Google Scholar
  548. Vaughan Williams, Sekiya, A.: Prevention of arrhythmias due to cardiac glycosides by block of sympathetic beta-receptors. Lancet 1963 I, 420–421.Google Scholar
  549. Vinik, A. J., Pimstone, B. L., Hoffenberg, R.: Sympathetic nervous system blocking in hyperthyroidism. J. clin. Endoer. 28, 725–727 (1968).Google Scholar
  550. Visioli, O., Bertaccini, G.: Combined propranolol and quinidine treatment in cardiac arrhythmias. Amer. Heart. J. 75, 719 (1968).PubMedGoogle Scholar
  551. Vogel, H. K., Chidsey, A.: Cardiac adrenergic activity in experimental heart failure as assessed with beta-receptor blockade. Amer. J. Cardiol. 24, 198–208 (1969).PubMedGoogle Scholar
  552. Vogel, J. H., Blount, S. G.: Modification of cardiovascular responses by propranolol. Brit. Heart. J. 29, 310–316 (1967).PubMedGoogle Scholar
  553. Waal, H. J.: Hypotensive action of propranolol. Clin. Pharmacol. Ther. 7, 588–598 (1966).PubMedGoogle Scholar
  554. Waal, H. J.: Propranolol-induced depression. Brit. med. J. 1967 II, 50.Google Scholar
  555. Waal, H. J.: Hypotensive, antiarrhythmic and chronotropic action of Trasicor (Ciba 39089-Ba). N. Z. med. J. 67, 291–295 (1968).PubMedGoogle Scholar
  556. Wagner, J., Fratz, R., Greeff, K.: Der Einfluß ß-adrenolytischer Substanzen auf die Wirkung der Digitalisglykoside. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 257, 75–76 (1967).Google Scholar
  557. Wagner, J., Greeff, K., Heeg, E., Pereira, E.: Unspezifische Wirkungen der Beta-Rezeptoren- blocker. Naunyn-Schmiedebergs Arch. cxp. Path. Pharmak. 253, 92–93 (1966).Google Scholar
  558. Waldstein, S. S.: Thyroid-catecholamine interrelations. Ann. Rev. Med. 17, 123–132 (1966).PubMedGoogle Scholar
  559. Wallace, A. G., Troyer, W. G., Lesage, M. A., Zotti, E. F.: Electrophysiologic effects of isoproterenol and beta-blocking agents in awake dogs. Circulât. Res. 18, 140–148 (1966).Google Scholar
  560. Wansborough, H., Nakanishi, H.: The effect of adrenergic receptor blocking drugs on the human uterus. J. Obstet. Gynaec. Brit. Cwlth 75, 189–198 (1968).Google Scholar
  561. Warkentin, L., Valenca, M. R.: Response of hyperkinetic heart syndrome to beta-adrenergic receptor blockade. Clin. Res. 13, 404 (1965).Google Scholar
  562. Warner, W. A.: Beta-adrenergic blocking agents and anaesthesia: a review. Canad. Anaesth. soc. J. 15, 42–55 (1968).PubMedGoogle Scholar
  563. Watt, D. A. L.: Sensitivity to propranolol after digoxin intoxication. Brit. med. J. 1968 IV, 413–414.Google Scholar
  564. Weissel, W.: Propranolol in digitalis induced arrhythmia. Wien. klin. Wschr. 79, 354–355 (1967).PubMedGoogle Scholar
  565. Whitsitt, L. S., Lucchesi, B. R.: Effects of beta-receptor blockade and glucagon on the atrioventricular transmission system in the dog. Circulat. Res. 23, 585–595 (1968).PubMedGoogle Scholar
  566. Wiener, L., Stout, B. D., Cox, J. W.: Influence of beta sympathetic blockade (Propranolol) on the hemodynamics of hyperthyroidism. Amer. J. Med. 46, 227–233 (1969).PubMedGoogle Scholar
  567. Wilson, D. F., Turner, A. S.: Clinical impressions of a new beta-adrenergic blocking drug, 39.089/Ba. N.Z. med. J. 66, 682–683 (1967).PubMedGoogle Scholar
  568. Wilson, W. R., Theilen, E. O.: Beta-adrenergic receptor blocking drugs as physiological tools in clinical medicine. Ann. N.Y. Acad. Sei. 139, 981–996 (1967).Google Scholar
  569. Wilson, W. R., Theilen, E. O.: Connor, W. E.: Metabolic effects of isoproterenol and propranolol in normal subjects before, during and after triiodothyronine-induced hypermetabolism. Proc. Soc. exp. Biol. (N.Y.) 124, 298–303 (1967).Google Scholar
  570. Wittenberg, S. M., Lown, B.: Cardioversion and digitalis. IV. Effect of beta-adrenergic blockade. Circulation 39, 29–37 (1969).PubMedGoogle Scholar
  571. Wolfson, S., Gorlin, R.: Cardiovascular pharmacology of propranolol in man. Circulation 40, 501–513 (1969).PubMedGoogle Scholar
  572. Wolfson, S., Heinle, R. A., Herman, M. V., Kemp, H. G., Sullivan, J. M., Gorlin, R.: Propranolol and angina pectoris. Amer. J. Cardiol. 18, 345–353 (1966b).PubMedGoogle Scholar
  573. Wolfson, S., Robbins, S. I., Krasnow, N.: Treatment of cardiac arrhythmias with beta-adrenergic blocking agents. Clinical and experimental studies. Amer. Heart. J. 72, 177–187 (1966a).Google Scholar
  574. Yamanura, H. I., Horita, A.: A further study of the effect of propranolol on the blockade of alpha adrenergic receptors. Europ. J. Pharmacol. 7, 258–263 (1969).Google Scholar
  575. Zaid, G., Beall, G. N.: Bronchial response to beta-adrenergic blockade. New. Engl. J. Med. 275, 580–584 (1966).PubMedGoogle Scholar
  576. Zaid, G., Beall, Heimlich, E. M.: Bronchial response to exercise following beta-adrenergic blockade. J. Allergy 42, 177–181 (1968).Google Scholar
  577. Zierott, G., Meyer, C., Lundsgaard-Hansen, P.: Effects of beta-receptor blockade on the course of experimental hemorrhagic shock. Z. Kreisl.-Forsch. 58, 892–903 (1969).Google Scholar
  578. Zöllner, N., Lohmöller, G., Schnelle, K., Lydtin, H.: The effects of cardiac glycosides and of a beta-receptor blocking agent on the ULF displacement ballistocardiogram in healthy young men. Proceedings of the 2nd world congress on ballistocardiography and cardio-vascular dynamics. Basel-New York: Karger 1969.Google Scholar
  579. Zsoter, T., Tom, H.: Adrenoceptive sites in the veins. Brit. J. Pharmacol. 31, 407–419 (1967).PubMedGoogle Scholar
  580. Zsoter, T., Kraml, M., Dvornik, D.: Adrenergic beta receptors and plasma free fatty acids. J.Pharmacol, exp. Ther. 152, 425–431 (1966).Google Scholar

Copyright information

© Springer-Verlag, Berlin · Heidelberg 1970

Authors and Affiliations

  1. 1.Medizinischen PoliklinikUniversität MünchenDeutschland

Personalised recommendations